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ABSTRACT 
CHARACTERIZATION OF A MORE CLINICALLY RELEVANT HUMAN 
LEUKEMIA XENOGRAFT MODEL TO EXAMINE PERTURBATION OF 
MET/SAM METABOLISM AS A NOVEL THERAPEUTIC PARADIGM FOR MLL-
R LEUKEMIA IN VIVO 
Aditya Barve 
July 26th, 2019 
Acute myeloid leukemia (AML), is a heterogeneous clonal disorder 
characterized by an accumulation of malignant myeloid progenitors in the bone 
marrow (BM), hindering normal hematopoiesis. AML exhibits dramatic 
heterogeneity in terms of cytogenetics, morphology, and chemotherapeutic 
sensitivity. Therefore, the investigation of novel, efficacious AML therapeutics will 
require advanced preclinical in vivo model systems, capable of recapitulating 
patient specific disease heterogeneity, and induction chemotherapy outcomes. A 
major focus and eventual outcome of this work was the establishment and 
development of a more clinically relevant mouse xenograft model of patient AML, 
that efficiently harbors patient derived xenografts (PDXs), and unlike more
v 
prevalent SCID models can tolerate more clinically relevant doses of DNA 
damaging induction chemotherapy. 
We examined the functional utility of our newly established, advanced 
AML PDX model to confirm our in vitro findings that perturbation of methionine 
(Met) / S-adenosylmethionine (SAM) metabolism is uniquely cytotoxic to MLL-
rearranged (MLL-R) leukemic cells, in vivo. We demonstrate here that 
perturbation of Met/SAM metabolism decreases intracellular methylation 
potential, alters global histone methylation dynamics, impairs the expression and 
function of the H3K79 methyltransferase DOT1L, and induces apoptosis in MLL-
R leukemic cells. We show a significant extension in the survival of mice 
harboring aggressive patient MLL-R leukemias, when treated with a 
pharmacologic inhibitor of Met/SAM metabolism and induction therapy, as 
compared to induction alone. The work featured in this dissertation establishes a 
novel chemotherapy tolerant AML xenograft model, demonstrates its translational 
utility, and supports the continued investigation of targeted inhibition of Met/SAM 
metabolism against MLL-R leukemia.
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BACKGROUND AND INTRODUCTION 
1.1 Acute Myeloid Leukemia 
The highly heterogeneous clonal disorder, acute myeloid leukemia (AML), 
is defined by an accumulation of malignant immature myeloid progenitors in the 
bone marrow (BM) and peripheral blood (rarely the central nervous system), that 
exhibit a block in normal hematopoietic differentiation. The high degree of 
observed disease heterogeneity is dependent largely on which particular myeloid 
progenitor acquires oncogenic mutations, and during which stage of normal 
hematopoiesis the oncogenic lesions occur.1 AML is the most prevalent form of 
adult leukemia and the second most common childhood leukemia, and the 
incidence of de novo AML has risen by 2.2% every year for the last 15 years. 
There will be an estimated 21,380 new cases of AML diagnosed this year in the 
U.S., many of them children. Modern remission induction chemotherapy of AML 
using an anthracycline (doxorubicin, daunorubicin, or idarubicin) combined with 
cytarabine, results in approximately 60-70% initial remission rates, but 
unfortunately the overall 5-year survival remains poor at only 26%, due largely to 
refractory relapse.2 Clinical care of AML has stagnated since the advent of 
induction therapy in the 1970s and remains the only approved standard of care
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(SOC) frontline therapy for AML, irrespective of the dramatic heterogeneity of 
patient AML in terms of cytogenetics, disease morphology, associated 
prognoses, and induction chemotherapeutic sensitivity. Therefore, novel patient-
tailored therapies and/or treatment paradigms that are more efficacious, specific 
to patient cytogenetics, and better tolerated by elderly and infant patients should 
be investigated in conjunction with SOC therapy.3 
The extreme heterogeneity of AML in terms of cytogenetics, morphology, 
and therapeutic sensitivity present a unique challenge for oncologists both in 
terms of treatment, and in classification. Initially, AML was classified according to 
the French-American-British (FAB) classification system, which groups various 
sub-types of AML based mainly on morphology, immunological phenotype, and 
basic cytochemical criteria into eight major subtypes (FAB M0 to M7).4 The FAB 
classification system was initially established by light microscopy of malignant 
cells, as well as some limited cytogenetic characterization of recurrent genetic 
abnormalities. The numerical hierarchy of the classification system corresponds 
to the relative degree of maturity (lowest being the least differentiated), as well as 
the progenitor cell type from which the leukemia developed. 
The FAB classification system was revolutionary in redefining our 
understanding of AML as a group of related neoplasms rather than a single 
disease, and clearly recognized distinct morphology and cytogenetics as key 
determinants of clinical outcomes and overall prognosis. However, this system 
was found to be somewhat oversimplified, and severely lacking in certain 
instances. The FAB classification system works well only in instances where the 
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observed genetic lesions directly induce the observed cellular morphology and 
cytochemical signaling. For example, in acute promyelocytic leukemia (APL, M4 
subtype), or APL with abnormal eosinophils (M4Eo) the morphological 
characteristics directly predict the genetic abnormalities, making these 
classifications highly accurate.5 However, as research and screening 
methodologies progressed and improved, it became evident that 
morphology/cytochemisty did not always correlate with or predict observed 
genetic abnormalities. Furthermore, patients diagnosed with the same proposed 
sub-type of AML by morphology and immunological phenotyping, often exhibit 
differences in observed genetic lesions. Additionally, there are many cases 
where there is absolutely no correlation between observed genetic defects and 
morphology, emphasizing the point that genetic profiling of AML provides a more 
accurate system of classification and prognostic prediction. While the FAB 
system was revolutionary in its recognition and characterization of AML as a 
group of related myeloid neoplasia, based on morphology and cytochemical 
heterogeneity, it does not accurately convey the genetic diversity and associated 
clinical outcomes of the disease sub-types. 
In response, the World Health Organization (WHO) developed an 
alternate classification system in 2001, based on the central concept that the 
sub-types of AML are actually distinct diseases through correlation of genetic, 
morphologic, and clinical data. This new system of classification differs 
significantly from the FAB system as it defines cases of AML into unique sub-
groups based on biological, clinical, and importantly genetic characteristics. The 
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WHO classification system was updated in 2008 to its current format which, like 
the FAB system, defines seven major AML subtypes: 1.) AML with recurrent 
genetic abnormalities, 2.) AML with myelodysplatic related changes, 3.) therapy-
related myeloid neoplasms, 4.) Myeloid sarcoma, 5.) Myeloid proliferations 
related to Down Syndrome, 6.) Blastic plasmacytoid dendritic cell neoplasm, and 
7.) AML otherwise not categorized.6 Each major subtype is divided into specific 
subcategories based on commonly observed recurrent genetic abnormalities, 
detailed karyotype analyses, and molecular abnormalities, providing a much 
better representation of the vastly differing genetic landscape of AML even in 
morphologically similar cases. It is evident that the WHO system of classification 
is far superior to the FAB system in terms of scope and descriptiveness, and 
therefore has been universally adopted as the chosen classification methodology 
for AML. 
1.2 Clinical Therapy of AML 
Contemporary SOC cytotoxic chemotherapy for AML is divided into two 
distinct phases, namely induction therapy and consolidation therapy. The first 
phase is designed to dramatically reduce the leukemic blast burden in the 
periphery as well as the bone marrow, and eventually induce remission. Intensive 
induction therapy is effective in inducing complete remission (CR) in 60-70% of 
patients who are able to tolerate therapy. Sadly, over 45% of patients achieving 
initial CR have a less than three-year overall survival due to relapse of refractory 
disease. The SOC induction therapy regimen for young adults and healthy 
elderly patients is commonly referred to as “7+3”, and utilizes a continuous 
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intravenous (IV) infusion of a DNA damaging anthracycline (60 or 90mg/m2) 
administered the first three days along with continuous infusion of cytarabine 
(Ara-C, 100mg/m2) for all seven days of therapy. As aforementioned, the goal of 
induction therapy is to induce CR, which is clinically defined as less than 5% 
blasts in the spicule containing BM aspirate, as well as a platelet count greater 
than or equal to 100,000 cells/ml of blood and absolute neutrophil count greater 
than 1000 cells/ul.6-8 
The second phase of AML therapy, consolidation therapy, aims to prevent 
subsequent disease relapse by reducing the minimal residual disease (MRD) 
burden, or the surviving leukemic blasts and founder cells which remain 
protected from cytotoxic drug exposure deep in the BM niche microenvironment. 
These cells, which survive the initial induction therapy, are the causative agents 
of refractory relapse resulting in patient mortality, and currently no FDA approved 
therapies exist for relapsed and/or refractory AML. Oncologists have two options 
for consolidation: 1.) HSC transplantation (HSCT) usually by allogenic BM 
transplant or 2.) Additional chemotherapy with intermediate dose cytarabine 
(1.5g/m2) twice daily on days 1, 3, and 5 in 3-4 cycles. These strategies are used 
alone or in combination at the clinician’s discretion based on the patient’s ability 
to tolerate aggressive chemotherapy, the availability of compatible BM donors, 
and the patient’s AML subtype. Chemotherapeutic consolidation therapy (3-4 
cycles) alone has been shown to effectively improve survival and lengthen 
remission in patients less than 60 years of age, leaving HSC transplant as a last 
resort in the result of relapse. Comparisons of high dose (3 g/m2) and 
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intermediate dose (1.5 g/m2) cytarabine show equal benefit for patients under 60 
years of age and therefore the intermediate dose became the standard of care, 
while the high dose regimen showed greater efficacy in patients with CBF AML 
[t(8:21); or inv(16)] or AML with mutated NPM1.9,10 
In certain prognostic groups, HSCT remains the most effective long-term 
therapy for AML, with up to 60% of transplanted patients achieving CR. Yet, 
many patients are deemed ineligible for HSCT due to lack of suitable donors, co-
morbidities, or a failure to achieve CR during the induction phase. Age, was 
initially thought to be the key determining factor in whether or not to use HSCT, 
but new evidence has conclusively shown that transplant success is actually 
dependent on remission status and co-morbidities. Improvements in conditioning 
regimens, supportive care, and haplo-identical/cord grafts have allowed for a 
larger percent of AML patients to become eligible for HSCT. The risk of relapse 
remains significantly higher in patients treated with HSCT alone, and again many 
patients are ineligible for transplant due to age or underlying co-morbidities.11,12 
Therefore, the investigation of new well-tolerated therapeutics, especially ones 
targeting patient specific genetic lesions, will be crucial to improving clinical 
therapy of AML. 
1.3 Heterogeneity of AML presentation and common genetic abnormalities  
Chromosomal irregularities (deletions, translocations, tandem repeats 
etc.) are observed in the majority of primary AML cases (approximately 50%), 
and are well recognized as causative events driving leukemic progression and 
transformation.9 These chromosomal abnormalities are directly correlated with 
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varied patient survival, treatment outcomes, and remission duration making 
cytogenetic analysis of AML a critical factor in determining treatment modalities. 
For instance, AMLs harboring t(8;21)(q22;q22), inv(16)(p13.1q22), or 
t(15;17)(q22;q12) have a universally better prognosis, and prolonged survival 
time as compared to other irregularities, like alterations involving chromosomes 5 
and 7 (complex karyotype AML) or 11q23, which are associated with shorter 
survival and diminished chemotherapeutic sensitivity.13 Often, these genetic 
abnormalities can lead to the expression of characteristic aberrant fusion proteins 
(AML-ETO, PML-RARA, mixed lineage leukemia [MLL] fusions, DEK-CAN, etc.), 
most of which have been directly implicated in driving oncogenic transformation 
and blocking normal hematopoiesis through altered epigenetic regulation of gene 
expression. Interestingly, approximately 40-50% of all AML cases are actually 
cytogenetically normal (CN-AML) using conventional analysis,14 demonstrating 
convincingly that AML associated genetic irregularities are not the only factor at 
play during the development of myeloid leukemia. Recent work is now starting to 
show that the presence or absence of specific mutations and/or altered 
regulation of gene expression can be used to further delineate various types of 
AML (especially CN-AML), and possibly provide novel avenues of targeted 
therapy. 
Experts are only beginning to understand the effects of dysregulated gene 
expression patterns and mutation status, on transformation and 
leukemogenesis.5 This is of special importance in people diagnosed with CN-
AML, which appears normal according to karyotyping analysis, and lack obvious 
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genetic lesions found in other AML subtypes. As such, the prognostic value of 
cytogenetic analysis is limited in these patients, but with the advent of next-
generation sequencing, the genetic portrait of CN-AML has become much 
clearer. It is now understood that on average CN-AMLs have 13 mutations, five 
of which are recurrent “driver” mutations (directly causing leukemogenesis) and 
eight are recurrent random “passenger” mutations.15 These mutations result in 
molecular abnormalities in the proteins produced, and these abnormalities are 
now being identified as key mediators of AML pathogenesis, as well as valuable 
prognostic markers accurately predicting clinical outcome, and as novel 
druggable targets for new therapeutic approaches.16 Mutations in several 
proteins namely, nucleophosmin 1 (NPM1), Fms-Like Tyrosine kinase (FLT3), 
and DNA methyltransferase 3A (DNMT3A) have come to the forefront of 
investigation due to their very high relative frequency in AML, and their influence 
on prognosis and treatment outcomes. 
NPM1 mutations are the most recurrent molecular abnormality observed 
in AML patients, and can be detected in approximately 25-30% of patients.17,18 
These mutations result in the expression of a mutated protein lacking a folded C-
terminal domain, which alters sub-cellular localization from the nucleus to the 
cytoplasm, and this transition has been shown to greatly promote myeloid 
proliferation and leukemogenesis. AMLs harboring these mutations generally 
present with monocytic morphology, and have generally favorable prognostic 
outcomes in the absence of other mutations (e.g. FLT3 internal tandem 
duplications [FLT3-ITD]).19 AMLs with NPM1 mutations have been conclusively 
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shown to have a greater sensitivity to SOC induction chemotherapeutics and the 
overall survival is greatly increased in both old and young patients as compared 
to other molecular abnormalities.20 However, NPM1 mutations are also 
associated with several other recurrent abnormalities like DNMT3A mutations, 
FLT3-ITDs, and isocitrate dehydrogenase mutations, most of which in 
conjunction with NPM1 mutations actually worsen the prognosis.21 Again, this is 
a clear demonstration of the inherent heterogeneity of AML, and the importance 
of cytogenetic analyses to examine potential molecular abnormalities, and guide 
therapeutic intervention.         
FLT3 was first identified as a critical regulator of normal hematopoiesis, 
playing crucial roles in mediating proliferation and cell survival during 
hematopoiesis. FLT3-ITDs in the juxta-membrane coding domain or the second 
tyrosine kinase domain are detected in approximately 20% of all AML cases, and 
30-45% of CN-AML. These mutations constitutively activate FLT3 promoting 
aberrant, unchecked proliferation of AML blasts.22-24 Patients with AML 
expressing FLT3-ITDs exhibit extreme leukocytosis and characteristic nuclear 
invagination, and these mutations are universally associated with reduced 
survival, decreased induction therapeutic sensitivity, and an increased risk of 
relapse. When FLT3-ITDs occur in combination with other commonly recurring 
AML mutations they correlate with diminished survival and increased relapse 
rates, even when occurring with other normally favorable alterations, like NPM1 
mutations. Finally, studies have shown that AML with mutations occurring in the 
non-juxta domain coding regions have a worse prognosis, again highlighting the 
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heterogeneity of AML and the clinical significance of mutational status as 
predictive biomarkers for patient outcome and to guide therapeutic approaches.25 
Mutations of the DNMT3A gene are detectable in approximately 18-22% 
of all AML cases (34% in CN-AML), the most common being missense mutations 
affecting arginine codon 822.21 These mutations have now been found to actually 
be pre-leukemic and arise very early in the evolution of the disease, but also 
persist even in times of CR. This finding is significant in that these mutations are 
perhaps the most common mutations involving proteins that regulate gene 
expression in AML.26 DNMT3A is a de novo methylase that is capable of 
methylation of CpG dinucleotides in the promoter regions of target genes, 
thereby mediating transcriptional silencing by blocking access of transcriptional 
machinery to these promoters. This form of regulation, which is independent of 
the genetic sequence, is known as epigenetic regulation and only very recently 
have methylation and other epigenetic mechanisms become recognized as 
relevant to leukemogenesis.27 Therefore it is logical that these mutations occur 
very early in leukemic development, and may even play a causative role in AML, 
by silencing genes required for maintenance of normal myeloid differentiation 
and hematopoiesis. Finally, the value of DNMT3A mutations as prognostic 
indicators remains hotly debated with some smaller studies finding a lowered 
overall survival (OS) and disease free survival (DFS) in patients expressing these 
mutations, while a much larger cohort study found no correlation between 
DNMT3A mutation status and clinical outcome.21,28 
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While these three mutations have the highest relative frequency of 
occurrence overall in AML and occur irrespective of cytogenetic irregularities, it is 
important to recognize that they represent only a small fraction of the vast array 
of combinations of molecular and genetic abnormalities that have been 
documented in AML. Furthermore, it becomes evident that AML in reality is a 
group of extremely heterogeneous related myeloid neoplasias in terms of 
morphology and cytogenetics, but more importantly these differences have been 
shown to result in drastically different therapeutic outcomes and overall survival. 
Therefore, the successful development of novel targeted AML therapeutics and 
treatment paradigms, will require advanced in vivo model systems capable of 
faithfully recapitulating the extreme genetic, epigenetic, and morphologic 
variation found in primary AML. Such advanced systems must also be able to 
replicate SOC induction therapy, not only as more relevant control (as opposed 
to vehicle only), but also as a more clinically applicable way to test experimental 
therapeutics and their translational/combinatorial efficacy. 
1.4 Epigenetic dysregulation and heterogeneity in AML 
Recently, epigenetic dysregulation has come to the forefront as a driving 
mechanism for the induction and maintenance of AML, and more than two thirds 
of patients with de novo AML have detectable epigenetic alterations.29 Aberrant 
epigenetic regulation interferes with the physiological balance between gene 
activation/repression required for normal hematopoiesis and differentiation, 
resulting in the leukemic phenotype. The influence of epigenetic changes is only 
recently starting to be fully understood in the context of both normal and 
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malignant hematopoiesis. Early epigenetic changes are crucial to normal 
hematopoiesis as they regulate successive gene expression profiles that give 
rise to all immune and hematopoietic lineages.30,31 For examples, DNA and 
histone methylation are required to silence the expression of transcription factors 
like RUNX1 and GATA3, which are required for self-renewal and pluripotency, 
thereby allowing differentiation.32 Additionally, epigenomic analysis of normal 
hematopoietic stem cells (HSCs) has shown that promoter regions of 
transcription factors crucial for myeloid differentiation (C/EBPα, EBF1, PU.1, 
PAX5 etc.) show low levels of DNA methylation and are enriched for bivalently 
methylated histones (having both activating [H3K4me3] and repressing 
[H3K27me3] marks).33 Dysregulation of these processes in AML is well 
documented and consistent aberrant DNA and histone methylation profiles are 
observed in a majority of analyzed patient samples. Interestingly, the various 
subtypes of AML have unique profiles of distinct aberrant methylation, findings 
that both highlight the importance of epigenetic regulation in the context of AML, 
and provide a new investigational avenue for targeted, patient specific therapy. 
Persuasive studies from several groups have demonstrated that many well 
defined AML genetic lesions, like chromosomal translocations resulting in 
characteristic oncogenic fusion proteins (e.g. PML-RARα, AML1-ETO, CBFβ-
MYH11, MLL-fusions etc.), or mutations in key transcription factors or epigenetic 
regulators (e.g. DNMT3A, NPM1, TET2 etc.) can result in aberrant recruitment of 
a variety of epigenetic modifiers (DNMTs, HMTs, HDACs, etc.) to target genes 
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and associated promoter histones resulting in abnormal leukemic gene 
expression.34,35 
These non-random chromosomal translocations and the resulting gene 
rearrangements and oncofusion protein expression, are exhibited by the majority 
of AML cases.36 Many of these chromosomal translocations involve loci encoding 
transcriptional activators of myeloid differentiation with transcriptional effector 
proteins capable of interaction with co-activator or co-repressor complexes. The 
resultant fusion protein retains the DNA-binding ability of the wild-type 
transcriptional activator, but gains the capacity to mediate epigenetic regulation 
of gene expression through interaction with co-activator or co-repressor 
complexes through its fusion moiety.37 AML therefore arises through a complex 
multi-stage process mediated by an accumulation of genetic and epigenetic 
changes, with the most common being recurrent genetic aberrations and their 
associated oncofusion protein expression.38-40 Aberrant recruitment of epigenetic 
modifiers by oncofusion proteins to the promoters of embryonic genes or genes 
critical to myeloid differentiation, disrupts normal hematopoietic gene expression 
resulting in AML. Consequently, normal patterns of DNA methylation and histone 
modifications are disrupted in leukemic blasts, in a sub-type specific manner 
depending on their driving oncofusion protein.41 Overall, the most common AML 
fusion proteins can be grouped based on those that gain repressor activity (PML-
RARα, AML1-ETO, and CBFβ-MYH11) thereby silencing gene expression and 
those that activate gene expression (Mixed lineage leukemia [MLL]-fusions) 
through altered epigenetic regulation. 
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Fusion proteins that gain repressive function have been shown to do so 
through their interaction and recruitment of transcriptionally repressive epigenetic 
modifiers. For example, both PML-RARα and AML1-ETO fusions have been 
shown to suppress gene expression through the direct recruitment of DNMTs to 
various promoters, or the recruitment of co-repressor complexes (Sin3A, N-CoR, 
and SMRT) and HDACs resulting in gene silencing. Interestingly, the CBFβ-
MYH11 fusion only mediates gene silencing through recruitment of Sin3A or N-
CoR and HDAC8. PML-RARα can also silence gene expression through altered 
histone methylation mediated through recruitment of the Polycomb complex.38 A 
common feature of these fusions is their abnormal ability to recruit repressive 
epigenetic machinery to the promoters of genes required for myelopoiesis 
thereby silencing their expression and driving AML. 
Alternatively, MLL-fusions aberrantly activate and maintain gene 
expression at inappropriate times through a variety of epigenetic mechanisms 
including histone acetylation, histone methylation, or through interaction with the 
nucleosome remodeling complex SWI/SNF. The normal MLL (MLL1) protein is 
an activator of transcription, which works antagonistically to PcG proteins to 
maintain appropriate lineage and stage specific expression of the HoxA gene 
cluster, events crucial for proper hematopoietic differentiation. MLL can directly 
activate transcription by catalyzing H3K4 methylation through the HMT activity of 
its C-terminal SET domain42,43, and has been shown to be fused in-frame with 
more than 60 different gene partners through its non-catalytic transactivatory N-
terminus, in several types of leukemia. MLL rearrangement (MLL-R) correlates to 
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highly aggressive disease that is poorly treated by SOC induction with extremely 
high rates of relapse and low overall survival.  MLL gene fusion partners are 
diverse and range from cytoplasmic proteins to nuclear factors, and are 
associated with AML, acute lymphoid leukemia (ALL), or biphenotypic/mixed 
lineage leukemias depending on the fusion moiety. However, approximately 80-
90% of all MLL translocations in leukemia involve only one of six genes, all 
members of super elongation complex (SEC), namely AF4, AF6, AF9, AF10, 
ENL, or ELL.44 The other detected fusion partners occur at an extremely low 
frequency, and many of them are identified in case studies only. Recently, 
published studies have suggested quite conclusively that the six most common 
MLL fusion partners share a common biochemical mechanism, by which they 
modulate aberrant promoter histone methylation leading to leukemogenic gene 
expression.  
 
1.6 MLL-fusion protein signaling and functional dependence on the histone 
methyltransferase DOT1L  
Chromosomal translocations resulting in rearrangement of the MLL1 gene 
have been associated with AML, ALL, and biphenotypic leukemia, and result in 
fusion of the catalytically inactive N-terminus of MLL to a variety of binding 
partners most commonly members of the SEC, suggesting an underlying general 
mechanism of action.45 Over the last decade elegant work published by several 
groups has shown that expression of several different MLL-fusions alone is 
sufficient to drive leukemic transformation irrespective of the fusion partner, and 
without additional cooperating mutations through the induction of widespread 
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epigenetic dysregulation, again suggesting a common mechanism for MLL-fusion 
mediated leukemogenesis.46-51 Analyses of gene expression patterns from 
patient leukemic blasts expressing several different MLL-fusions, have shown 
that MLL fusion proteins preferentially upregulate and maintain expression of a 
specific subset of wild-type MLL gene targets, most notably MEIS1 and the 
HOXA cluster, thus disrupting the normal progression of hematopoietic gene 
expression. Taken together these findings demonstrated overall that MLL-fusion 
proteins likely function through a common underlying mechanism influencing 
gene expression through aberrant recruitment of epigenetic machinery to 
lineage-specific developmental genes leading to their constitutive expression 
thus driving leukemogenesis.52-55 
Genome-wide histone methylation profiling of MLL-rearranged leukemias 
revealed profound abnormalities in the distribution of one particular histone 
modification, H3K79 methylation, further solidifying the idea that MLL-fusions 
drive leukemic progression and gene expression through epigenetic 
dysregulation. Early evidence further supported this conclusion as H3K79 
methylation is enriched at actively transcribed promoters and gene bodies, and 
this modification was found at high levels at the promoters of the most prominent 
MLL-fusion targets HOXA9 and MEIS1 in primary patient samples, human 
hematopoietic progenitors transformed by MLL-ENL, or human MLL-rearranged 
cell lines.56,57 These findings put particular emphasis on the importance of the 
histone methyltransferase Disruptor of telomeric silencing 1-like (DOT1L), the 
only known H3K79 methyltransferase, in MLL-fusion mediated leukemic gene 
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expression. Several MLL-fusions have been shown to interact with DOT1L, MLL-
AF10 being the first identified to physically interact with DOT1L. Later seminal 
work by Bitoun et. Al and Muller et. Al reported that the other common binding 
partners of MLL (AF4, AF5, AF9, AF10 and ENL) exist in a complex that also 
contains DOT1L and the pTEFb complex (phosphorylates stalled RNA 
polymerase II [Pol II] activating transcription), dubbed the ENL-associated protein 
or EAP complex. Furthermore, several other groups independently identified may 
similar complexes like AEP (containing AF4, AF5, ENL and pTEFb), a complex 
composed of AF4, AF9, ENL, AFF4, ELL1 and pTEFb, and DotCom (containing 
DOT1L, AF9, ENL, AF10, AF17, several WNT modifiers), which have collectively 
been termed super elongation complex (SEC).58-60 These discoveries prompted 
the now generally accepted hypothesis that when fused to the N-terminus of MLL 
retaining transactivation and DNA binding ability, each member of the SEC 
complex can subsequently miss-recruit the other SEC complex members 
including DOT1L to wild-type MLL target loci. Next, DOT1L presumably 
methylates H3K79 at MLL target promoters, inducing transcriptionally permissive 
open chromatin formation. Finally, pTEFb can recruit and stimulate the activation 
of RNA Pol II to allow aberrant constitutive transcription of several MLL gene 
targets, most notably HOXA9 and MEIS1. (Fig. 1.1) The extremely strong 
correlation between increased H3K79 methylation and MLL-fusion target loci has 
been dubbed an “epigenetic lesion”, emphasizing the unique expressional 
dependence of these loci on aberrant histone methylation.61  
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Figure 1.1 Mechanisms of DOT1L dependent MLL-R mediated 
leukemogenesis. Monoallelic translocations of the MLL gene result in the fusion 
of the catalytically inactive N-terminus in frame with a variety of partners, most 
commonly SEC complex members. These aberrant MLL fusion proteins (MLL-
FPs) directly drive leukemogenic gene expression by mistargeting of the SAM-
dependent activating H3K79 methyltransferase DOT1L to normally silenced 
developmental genes like the HOXA cluster and MEIS1, driving their irregular 
expression. Methylation of H3K79 by DOT1L at these promoters results in 
transcriptionally permissive conformational changes, and subsequently the 
functional MLL from the unfused allele can deposit the required transcriptionally 
activating H3K4me3. The SEC complex and RNA Pol II remain associated with 
the fusion partner portion of the MLL-FP, and can thus potently drive aberrant 
transcription of leukemogenic genes upon DOT1L mediated promoter 
euchromatin formation.  
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More recently, several groups have convincingly shown through various 
loss of function studies (shRNA-knockdown, pharmacologic inhibition, or 
conditional knockout) that DOT1L mediated activation of MLL gene targets like 
HOXA9 or MEIS1 through H3K79 methylation, is absolutely requisite for MLL-
fusion protein mediated leukemic transformation, progression and maintenance 
in vitro and in vivo. Elegant studies published by several groups have shown that 
genetic loss of DOT1L function is cytotoxic to MLL-rearranged cells and inhibits 
MLL-fusion induced transformation (as does deletion of the HOXA9 gene or 
mutation of H3K79), further supporting the currently accepted dogma of MLL-
fusion mediated leukemogenesis.62-64 Finally, these findings were confirmed by 
the in vitro and in vivo anti-proliferative/cytotoxic efficacy of several specific SAM 
competitive DOT1L small-molecule inhibitors against a variety of MLL rearranged 
cells, thereby confirming the results observed by genetic loss through 
pharmacologic inhibition of DOT1L catalytic activity.65-68 Currently, it appears 
well-established that DOT1L activity is required for the initiation, progression, and 
maintenance of MLL-rearranged leukemias through aberrant H3K79 methylation, 
driving the continuous abnormal expression of leukemogenic genes like HOXA9 
or MEIS1. Given the now well-established and crucial role of DOT1L in MLL-
rearranged leukemogenesis is mediated through the dysregulation of histone 
methylation dynamics, we next investigated the effects of perturbations to 
Met/SAM metabolism, a key metabolic pathway that determines the overall 
intracellular methylation potential, specifically in MLL-rearranged human 
leukemia in vitro and in vivo.        
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1.5 Methionine and S-adenosylmethionine metabolism 
The methionine (Met) and S-adenosylmethionine (SAM) metabolic 
pathway is essential for cellular methylation reactions, including those involved in 
epigenetic gene regulation, and SAM serves as the primary methyl donor for the 
majority of cellular methylation reactions, including DNA, RNA, lipids and histone 
methylation (both arginine and lysine)34,35. In addition to being the principal 
methyl donor for all cellular reactions, SAM also serves as the sole source of the 
propylamine moiety required for polyamine biosynthesis.69,70 The biologically 
usable SAM moiety is synthesized from methionine by the enzyme methionine 
adenosyltransferase 2A (MATIIA), and upon enzyme mediated donation of its 
methyl group SAM forms the product S-adenosylhomocysteine (SAH), which is 
further metabolized by SAH hydrolase (SAHH) to form homocysteine.71 
Homocysteine, is an obligatory intermediate in the transsulfuration pathway, and 
serves as the precursor for glutathione synthesis. Alternatively, homocysteine 
can be recycled back into methionine by the recycling enzyme methionine 
synthase (MTR), which catalyzes the final step in methionine regeneration by 
simultaneously converting 5-methyltetrahydrofolate to the biologically active 
cofactor tetrahydrofolate, while transferring a methyl moiety to homocysteine 
starting the cycle again.72 Importantly, the intracellular ratio of SAM:SAH dictates 
the overall methylation potential of the cell, with SAH accumulation resulting in 
global feedback inhibition of cellular methylation reactions, including epigenetic 
methylation of DNA or histones (Fig. 1.2).73 
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Figure 1.2 Simplified schematic of non-hepatic methionine and S-
adenosylmethionine metabolism. Dietary methionine (Met) is first converted 
into the principal biologically active methyl donor S-adenosylmethionine (SAM), 
by the enzymatic action of methionine adenosyltransferase IIA (MATIIA). S-
adenosylhomocysteine (SAH) is formed upon methyltransferase mediated 
donation of the SAM methyl moiety, and is further converted to homocysteine 
which can be recycled through methionine synthase mediated salvage. 
Importantly, the intracellular ratio of SAM:SAH determines the overall cellular 
methylation potential, therefore we chose to perturb Met/SAM metabolism and by 
extension methylation potential by either deprivation of exogenous methionine 
and/or DZA mediated SAHH inhibition and subsequent SAH accumulation. 
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Therefore, it is likely that Met/SAM metabolic flux and expression of the 
aforementioned enzymatic mediators are required at high levels selectively by 
MLL-rearranged leukemia cells, to maintain and enforce aberrant histone 
methylation contributing to the leukemic phenotype. Unlike genetic abnormalities, 
epigenetic modifications are frequently reversible, and therefore may provide 
new opportunities for targeted pharmacological therapies for MLL-rearranged 
AML. Published literature targeting this pathway specifically in MLL-rearranged 
leukemia is non-existent, and a very sparse body of work exists for targeting this 
pathway as a general anti-leukemic therapy, with studies limited to small in vitro 
studies using established human cell lines, and single agent pharmacological 
inhibition of MATIIA or SAHH.  Thus, this dissertation will rigorously investigate 
methionine deprivation with and without inhibition of downstream enzymatic 
mediators of the biosynthetic pathway (SAHH) in vitro and in vivo, as a novel 
epigenetic treatment paradigm for MLL-rearranged leukemias, which have a 
unique dependence on aberrant histone methylation to activate and maintain 
enforced leukemic gene expression promoting leukemic survival and 
proliferation. 
1.6 Advantages of in vivo pre-clinical modeling of AML 
Animal models have consistently been shown to better predict the long-
term success of experimental therapeutics in clinical trials, especially for novel 
AML therapeutics, as in vivo systems are capable of modeling the complex, 
highly dynamic interaction between heterogeneous populations of leukemic cells 
and the surrounding BM microenvironment.74 Current evidence supports the 
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conclusion that specific niches within the BM microenvironment actually provide 
a protected sanctuary for specific subpopulations of leukemic cells capable of 
self-renewal and clonogenic proliferation, dubbed leukemic stem cells (LSCs). 
Seminal studies using early xenograft models were able to establish that only the 
most primitive fraction (Lin-CD34+) of patient AML cells, and not the more mature 
blast population, were capable of transferring disease to primary and secondary 
NOD/SCID recipient mice.75,76 It becomes evident that a hierarchy similar to 
normal hematopoiesis exists in AML, with a small population of self-renewing 
LSCs giving rise to a large population of mature, clonally expanded blasts. LSCs 
are able to evade normal induction chemotherapy, due to their low rate of 
proliferation and protection conferred by the BM microenvironment, and therefore 
are thought to be the cause of the high relapse rate and mortality associated with 
AML. Perhaps more alarming is the mounting data that these LSCs can actively 
induce changes in the BM microenvironment not only at the structural level, but 
in cytokine production and genetic/epigenetic abnormalities within supporting BM 
stromal cells.77,78 Co-culture experiments have shown that HSCs cultured on BM 
stroma collected from AML patients have a pronounced impairment in both self-
renewal and survival capacity, while LSCs lose neither attribute on AML or 
normal stroma. 
Thus, LSCs induce changes to the BM microenvironment and supporting 
cells, which favor LSC survival and maintenance while simultaneously 
compromising the ability to support and maintain normal HSC survival and 
differentiation. These interactions add another layer of complexity, additional to 
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the dramatic heterogeneity of AML, which again must be accounted for in model 
systems that will ultimately be useful in the development of successful 
therapeutic paradigms that will translate to clinical care. Again, in vivo animal 
studies remain the only reliable way to examine the highly complex interplay 
between leukemic populations (LSC and blast populations) and the protected BM 
niche, and by extension the pharmacological efficacy of novel therapeutics. 
Finally, in vivo methodologies have been shown to have significant advantages in 
predicting success rates of experimental drugs, as compared to in vitro 
techniques which often show success in the lab, but due to the lack of an 
accurate organ specific extracellular environment, cross talk between hormones 
or different cell types, differential metabolism, and site specific delivery fail to 
show efficacy in clinical trials.79 This remains especially true for AML, as effective 
novel therapeutics must be able to target the largely quiescent and protected 
LSC population residing in the bone marrow, or alternatively target the bone 
marrow microenvironment to make it unfavorable for leukemic growth or promote 
normal hematopoiesis.  
1.7 Immune deficient mice strains in AML research 
First developed in the 1960s, immune deficient mice overcame a major 
technical obstacle required for the successful xenotransplantation and durable 
engraftment of human tissues and cells. Highly immune deficient mice 
revolutionized the study of both normal and malignant hematopoietic processes 
and support the differentiation and continued growth of human xenografts in vivo. 
Characterized in 1962, nude or athymic mice, were the first immune-deficient 
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mice capable of accepting human cells and tissues, and since then there has 
been continued effort to improve patient sample engraftment through increased 
immune ablation.80 Shortly thereafter severe combined immune deficient (SCID) 
mice were developed, which lack the ability to initiate or maintain effective 
adaptive immune responses due to an absence of functional B or T 
lymphocytes.81 Immune ablation in these mice is achieved by a recessive 
mutation resulting in deficient activity of the enzyme protein kinase, DNA 
activated catalytic polypeptide (Prkdc), which impairs V(D)J recombination 
disrupting lymphocyte maturation.  Prkdc is also required for effective DNA 
damage repair, and thus SCID mice are highly sensitive to DNA damaging 
chemotherapeutics. SCID mice were found to be far superior in terms of human 
tissue engraftment, and further refinement and immune ablation to these models 
came with the development of non-obese diabetic (NOD)/SCID mice. Generated 
through the introduction of the Prdkcscid gene into an inbreeding NOD strain, 
NOD/SCID mice show consistently superior rates of human cell engraftment 
compared to SCID mice.82,83 Around the same time similar strains of mice 
displaying a SCID like phenotype were developed bearing a defective 
recombination activated gene (RAG, can be either Rag1/2null) and crossed with 
NOD mice resulting in NOD/Rag1/2null mice. These mice show equivalent 
immune ablation and engraftment efficiency of human hematopoietic tissues 
compared to the more prevalent NOD/SCID mice, but retain a functional DNA 
damage repair response.84,85 Further attempts were made to improve the durable 
long term engraftment, multilineage hematopoietic differentiation, and 
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proliferation of human hematopoietic xenografts through transgenic approaches 
allowing the expression of human hematopoietic cytokines in several iterations of 
NOD/SCID and NOD/RAG1/2null mice.86 
The early 2000s saw the arrival of a series of immune deficient mice with 
true humanization potential, capable of not only highly efficient engraftment of 
malignant human hematopoietic cells, but also well-differentiated multilineage 
expansion of normal human HSCs. These strains were developed by the 
introduction of a mutant IL2ry gene into NOD/SCID mice through respective 
backcross mating, generating perhaps the two most widely used immune 
deficient mice in hematological research, NOG and NSG mice, which are both 
NOD/SCID IL-2rynull but differ in the location of the SCID mutation.87,88 The IL-2ry 
is crucial to and B cell growth and is activated by several other interleukin 
cytokines including IL-2, IL-4, IL-7, IL-15, and IL-21. Thus, its inactivation allowed 
for enhance multilineage immune suppression and overcame inherent 
“leakiness” observed in NOD/SCID mice, which eventually develop both T and B 
lymphocytes with age.89 Inactivation of IL-2ry was also introduced into 
NOD/Rag1/2null mice, resulting in NRG [(NOD)/Rag1/2null IL-2rynull] mice whose 
equivalent immune impairment is dependent on hematopoietic specific RAG 
deficiency leaving DNA damage repair intact.90 
Functionally NOG, NSG, and NRG mice were a revolutionary leap in 
murine xenograft model of human leukemia and show deficiencies in multiple 
immune lineages well beyond lymphocytic impairment. Defects in T, B, and 
natural killer (NK) cell lineages are observed in these mice, as well as markedly 
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reduced macrophage and dendritic cell function.87 Dramatically enhanced 
engraftment rates of human HSCs, cell lines, and primary patient leukemia have 
been well documented in these strains, as well as well-defined multilineage 
expansion and maturation of several distinct human hematopoietic lineages upon 
normal human HSC xenotransplant when compared to parental strains. A 
particularly important finding was that these mice support the differentiation and 
proliferation of mature CD4 and CD8 single positive human T lymphocytes, which 
do not develop in NOD/SCID mice. These strains, particularly NSG mice, have 
become the predominant workhorses of hematological research focused on 
studying both human leukemogenesis and hematopoiesis, in an in vivo system 
that recapitulates many aspects of physiological conditions experience by normal 
and leukemic hematopoietic cells in the human body. Such advanced in vivo 
xenograft model systems are critical to effective preclinical investigation of novel 
experimental therapeutics that go on to have a high rate of success in clinical 
trials. 
It is now well recognized that many mouse cytokines do not show cross 
reactivity with receptors expressed on human cells, another significant hurdle in 
the successful engraftment of many patient samples. Furthermore, this is a major 
shortcoming as cytokine mediated signaling is known to be required for normal 
and malignant hematopoiesis, and plays a role in leukemic progression and 
therapeutic outcomes. Additionally, cytokine signaling is required for reliable 
homing, engraftment, and proliferation of both patient leukemia samples and 
normal human HSCs, which are notoriously difficult to engraft.91 In an effort to 
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overcome this problem several independent groups have developed various 
iterations of NOG and NSG mice expressing transgenes for a variety of human 
hematopoietic cytokines (e.g. hIL-2, hIL-3, hIL-6, hGM-CSF, etc.).92,93 These 
developments further improved hematological xenograft models by allowing for 
efficient engraftment, differentiation and proliferation of human hematopoietic 
cells in a BM specific in vivo microenvironment along with limited human cytokine 
signaling. 
Despite these great advances, the two most commonly utilized strains 
NOG and NSG mice have a major flaw in the context of investigation of novel 
leukemic therapeutics that is often overlooked. Mutation of the Prkdc gene, which 
impairs V(D)J recombination resulting in the SCID phenotype, also ablates its 
function in effective DNA damage repair. Therefore, these mice are highly 
intolerant to DNA damaging chemotherapeutics, which are the foundation for 
clinical therapy of leukemia, as they are unable to repair any drug induced DNA 
lesions. This poses a significant challenge especially for the investigation of 
novel AML therapeutics as the SOC frontline induction therapy combines an 
anthracycline with cytarabine, both DNA damaging compounds. Anthracyclines 
like doxorubicin or daunorubicin intercalate DNA thereby preventing 
macromolecular biosynthesis, while simultaneously stabilizing topoisomerase II 
promoting DNA strand breaks. Cytarabine (cytosine arabinoside, ara-C) 
interferes with DNA synthesis through rapid conversion to a toxic DNA damaging 
intermediate during S-phase DNA replication.94,95 Mice harboring SCID mediated 
immune deficiencies are therefore severely intolerant to treatment with these 
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drugs, even at doses that are subtoxic to other mouse strains, thereby 
diminishing their utility in the investigation of novel and efficacious antileukemic 
drugs. Effective translational models must be able to closely mimic patient 
experience, including SOC therapy, not only as a more relevant control but also 
in the investigation of innovative combinatorial therapeutics. 
Recently, in 2014, our collaborators at Cincinnati Children’s Hospital 
developed a new mouse strain by crossing NRG mice with NSGS mice, which 
are transgenic NSG mice harboring the SGM3 triple co-injected transgenes 
coding for expression of human IL-3, GM-CSF, and stem cell factor (SCF). After 
genotyping the offspring, subsequent selective breeding together or with NRG 
mice allowed for the removal of the SCID mutation resulting in NRGS mice, 
essentially SGM3 transgene expressing NRG mice.96 NRGS mice have no 
mature T, B, or NK cells due to hematopoietic RAG1 inactivation (as opposed to 
a SCID mutation) and also express the three aforementioned human cytokines, 
which are important for both the engraftment and support of human myeloid cells. 
Since NRGS mice lack a SCID mutation they have functional DNA damage 
repair and should therefore be tolerant to higher, more clinically relevant doses of 
induction chemotherapeutics. Indeed, published studies from our collaborators 
have shown that NRG mice are tolerant of doses of induction therapeutics that 
are highly toxic to NSG mice, and maintain the inherent radioresistance that is a 
hallmark of NRG mice.79 NRGS mice are truly cutting edge and uniquely suited to 
modeling both normal and malignant human myelopoiesis, the influence of the in 
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vivo hematopoietic microenvironment, human myeloid cytokine signaling, and 
aggressive SOC induction therapy and dose escalation. 
OVERALL GOALS AND SPECIFIC AIMS 
It is now well established that in vivo xenograft models using immune 
deficient mice consistently better predict the success of experimental 
therapeutics, especially those against AML, through their ability to model 
complex and dynamic interactions between leukemic cells and the protected BM 
niche. Animal models of human leukemia have continued to improve over time, 
with increasing immune ablation and transgenic human cytokine expression 
boosting xenograft establishment and engraftment.  However, despite decades of 
research, approved clinical therapy of AML has remained unchanged since the 
advent of cytotoxic induction therapy in the 1970, and no new AML therapeutics 
have been approved for frontline therapy (except in the case of APL) singly or in 
combination with the SOC. Furthermore, the majority of investigators utilize 
NOD/SCID IL-2Rγnull immune deficient xenograft models, whose SCID mutation 
and defective DNA repair render them intolerant to DNA damaging induction 
therapeutics like doxorubicin and cytarabine. It is therefore crucial to develop and 
establish a highly advanced, robust xenograft model of patient AML, is capable of 
highly efficient engraftment of patient cells, modeling the influence of human 
cytokines, and most importantly modeling therapeutic outcomes using a clinically 
similar induction therapy regimen. 
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Thus, the overall goals of this dissertation are to establish such a more 
clinically relevant advanced xenograft model of both cell line derived (CDX) and 
patient derived xenograft (PDX) human AML, and optimize a clinically similar, 
well-tolerated, and efficacious SOC induction therapy regimen to recapitulate 
clinical therapy. Furthermore, we examined the comparative utility of each strain 
in the investigation of CDXs, PDXs, response to SOC induction 
chemotherapeutics, and humanization potential. The final goal of this dissertation 
is to utilize such an advanced preclinical model to investigate therapeutic efficacy 
of targeted inhibition of Met/SAM metabolism against MLL-rearranged AML in 
vivo.  Preliminary in vitro data from our group has shown that perturbation of 
Met/SAM metabolism is cytotoxic to MLL-translocated leukemic cells and alters 
global histone methylation dynamics and gene expression, specifically 
decreasing the expression and function of the histone methyltransferase DOT1L. 
These findings must be confirmed in vivo to merit further investigation into the 
therapeutic potential of targeting Met/SAM metabolism. The outcomes of this 
study would aid in future preclinical investigation of successful AML experimental 
therapeutics in vivo, while simultaneously modeling therapeutic outcomes in 
combination with SOC therapy greatly enhancing the likelihood of success in 
clinical trials.  
Aim 1: Examine comparative engraftment efficiency of both malignant and 
normal hematopoietic cells, including humanization potential plus disease 
presentation of cell-line derived xenografts (CDXs) and primary and 
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secondary patient derived xenografts (PDXs) in unconditioned NRG and 
NRGS mice. 
Profound differences were observed in both engraftment rates and 
disease presentation in CDXs and PDXs in NRG and NRGS mice. As expected, 
unconditioned NRG mice were incapable of harboring different AML PDXs, and 
were determined to be ideal for CDX studies, showing predictable disease 
latency and diffuse clinically similar presentation in the blood and hematopoietic 
organs. Unconditioned NRGS mice showed high rates of PDX engraftment from 
secondary transplants and primary AML, but developed clinically dissimilar 
disease and solid tumor formation in CDXs, likely due to constitutive transgenic 
human cytokine expression. Thus, we have established and optimized the 
functional usefulness of both NRG and NRGS mice in human AML CDXs and 
PDXs. Our findings conclude that both NRG and NRGS mice are powerful tools 
for the investigation of malignant hematopoiesis, each with their own strengths 
and limitations, as determined contextually by the experimental design. 
Immune deficient mice, while indispensable to hematological research, 
have the inherent flaw of lacking functional immunity. Moreover, patient PDX 
models, which recapitulate patient specific disease lack the component of 
functional human immunity still present in patients, thereby limiting investigation 
of therapeutic efficacy, especially for novel immune therapies. Thus, we wanted 
to examine the differential humanization potential of unconditioned NRG and 
NRGS mice xenografted with normal enriched human umbilical cord blood (UBC) 
derived CD34+ HSCs. Our findings demonstrate that only unconditioned NRGS 
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mice, but not unconditioned NRG mice, are capable of durable long-term 
engraftment and multilineage expansion of human HSCs. Interestingly, our data 
showed that contrary to others findings, expression of human cytokines are not 
detrimental to human HSC engraftment and proliferation. Our findings suggest 
that the differences observed in other studies were likely attributable to the 
intense ablative pre-conditioning of the mice prior to xenograft, which we 
avoided. Thus, our data indicates that unconditioned NRGS mice support normal 
human hematopoiesis, and may indicate that ablative pre-conditioning of mice 
prior to humanization may be unnecessary and counterproductive.  
Aim 2: Develop and optimize a clinically similar, effective dosing regimen 
of induction therapeutics that is well tolerated in NRG and NRGS mice. 
The only approved frontline therapy for AML remains revolves around 
using a combination of an anthracycline and cytarabine, and has remained 
unchanged since the 1970s. However, the large majority of published pre-clinical 
studies involving experimental AML therapeutics compare efficacy only to a 
vehicle control, and sometimes rarely a single agent (usually cytarabine). In 
reality, the efficacy of new experimental therapeutics should be tested and 
compared to approved SOC therapeutic outcomes, which remains problematic 
due to the prevalence of SCID dependent xenograft model systems. To address 
these issues, we utilized SCID-independent NRG and NRGS mice harboring 
human AML CDXs and PDXs, and treated them with a modified 5+3 bolus IV 
induction regimen (3 mg/kg doxorubicin for the first three days and 75 mg/kg 
cytarabine all five days), using doses of chemotherapeutics that SCID mice 
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cannot tolerate, but more closely recapitulate patient experience. Additionally, we 
conducted dose escalation and treatment timing modulation studies using 
increased doses of either drug or starting treatment 7 or 25 days post xenograft. 
Our data indicate that NRG and NRGS mice can tolerate significantly higher and 
more clinically relevant doses of DNA damaging induction therapeutics, and 
furthermore our regimen is efficacious in prolonging the survival of mice 
harboring aggressive human AML xenografts.  
Aim 3: Investigate inhibition of Met/SAM metabolism as a novel therapeutic 
paradigm against MLL-rearranged leukemia in vivo, in an advanced 
xenograft model of patient AML, both against SOC induction and in 
combination. 
Preliminary in vitro data from our group has shown that perturbation of 
Met/SAM metabolism through methionine deprivation or pharmacological 
inhibition of downstream metabolism induces apoptosis in MLL-rearranged 
leukemia, alters global histone methylation dynamics, and decreases expression 
and function of the crucial histone methyltransferase DOT1L. DOT1L expression 
and activity are absolutely required to maintain proliferation and leukemic 
potential of MLL-rearranged leukemia, through mis-localization to normally 
silenced embryonic gene promoters driving expression. Loss of DOT1L 
expression or function is sufficient to stop MLL fusion protein induced leukemic 
transformation and inhibits the proliferation and survival of MLL-translocated 
leukemia cells. Inhibition of downstream Met/SAM metabolism significantly 
prolonged the life of mice xenografted with aggressive pediatric MLL-translocated 
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leukemia samples in combination with SOC induction therapy.  Thus, 
confirmation of our in vitro findings in vivo may reveal targeted inhibition of 
Met/SAM metabolism through dietary or pharmacologic methods, as a novel 




ESTABLISHING A MORE CLINICALLY RELEVANT MOUSE MODEL OF 
PATIENT AML AND STANDARD OF CARE CHEMOTHERAPY, TO 
INVESTIGATE THE THERAPEUTIC POTENTIAL OF ALTERATIONS TO 
MET/SAM METABOLISM 
INTRODUCTION 
The study of normal and malignant hematopoietic processes has truly 
been revolutionized by immune deficient mice, capable of supporting the growth 
and differentiation of human hematopoietic cells and tissues without rejection.97-
99 More importantly, in vivo xenograft models of human cancers consistently 
better predict the success of experimental chemotherapeutics in clinical trials, 
likely due to the complex and dynamic interplay existing between the BM 
microenvironment and heterogenous populations of leukemic cells.100 Several 
seminal studies using early human leukemia xenograft models showed that only 
the most primitive and undifferentiated fraction of patient leukemic cells 
(Lin-,CD34+), but not the mature blast population, was capable of transmitting 
disease to primary and secondary immune deficient mice. These cells were 
dubbed LSCs, and exist at the apex of a hierarchy similar to HSCs during normal 
hematopoiesis.76 This small population of slowly proliferating, self-renewing LSCs 
reside within the BM niche microenvironment, and can eventually give rise to a
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large population of rapidly proliferating, clonally expanded blasts. Furthermore, a 
large body of evidence supports the notion that specific niches within the BM 
provide a chemotherapeutic protected sanctuary which the LSCs occupy, thereby 
eventually driving lethal refractory relapse in the majority of patients who 
experience initial remission.101,102 Logically, it becomes evident that xenograft 
models of are the most reliable preclinical method capable of modeling the highly 
complex interplay among patient specific heterogenous leukemic populations, the 
BM microenvironment, clincal therapeutic outcomes, and by extension the true 
pharmacological efficacy and utility of novel investigational 
chemotherapeutics.103-105 Despite the great advances made in murine leukemic 
xenograft models many samples of patient AML fail to sufficiently engraft, likely 
due to the following factors: 1.) Improper homing to BM nice 2.) Residual mouse 
innate immunity, 3.) Absence of human cytokines, 4.) Lack of appropriate stromal 
support, or 5.) AML sample intrinsic factors. 
Transgenic approaches have dramatically enhanced the engraftment 
efficiency of human AML, by allowing the development of several iterations of 
immune deficient mice capable of expressing several human myeloid cytokines 
(IL-3, GM-CSF, and SCF), most frequently on NOD/SCID IL-2Rynull background 
mice in hematologic research. (NSGS, NSS, etc.). Human myeloid cytokine 
expression not only supports myelopoiesis and engraftment of a variety of patient 
AML samples, but also the establishment and multilineage expansion of mature 
human hematopoietic cells from CD34+ human HSCs.87,88,106,107 These 
advances, while indeed highly significant, are hindered by the reliance on SCID-
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mediated immune deficiency (Prdkcscid), which also impairs DNA damage repair, 
making these strains extremely intolerant to DNA damaging AML therapeutics 
like anthracyclines and cytarabine.79,100 Thus, it becomes impossible to model 
patient xenograft response to SOC therapy in the most commonly used strains in 
hematologic research, despite such data being an absolutely necessary 
component of more physiologically and clinically relevant in preclinical 
investigation of new efficacious AML therapeutics. In 2003, Schultz et. Al 
developed another strain of comparably immune deficient mice with an intact 
DNA damage response dubbed NRG mice (NOD/Rag1/2null IL-2Rynull), whose 
immune ablation is maintained through a defective RAG gene. 
Recently in 2014, in an effort to further improve engraftment rates of 
human AML samples in DNA damaging chemotherapeutic tolerant mice, NRG 
mice were crossed with human cytokine expressing NSGS (NSG-hIL3, h-GM-
CSF, hSCF) mice and the SCID mutation removed through selective 
backcrossing with NRG mice. The resultant strain called NRGS (NRG-SGM3) 
mice express human myeloid cytokines, display a comparable degree of immune 
ablation to SCID mice, and can likely tolerate higher doses of SOC therapeutics 
in a clinically similar dosing regimen.79 NRGS mice show consistent highly 
efficient engraftment of human hematopoietic cells, and can model the influence 
of the BM microenvironment, human cytokine signaling, and therapeutic 
outcomes. Given the recent development of these strains, and their relative lack 
of use in AML research, we next conducted an in-depth analysis of the 
comparative utility of unconditioned NRG and NRGS mice for the study of CDXs, 
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patient derived xenografts (PDXs), response to SOC chemotherapeutic treatment 
in clinically similar dosing regimen, and finally humanization potential using 
purified human HSCs.                                                                       
 
MATERIAL AND METHODS 
Cell Culture and Patient Samples. Established human AML cell lines K562, 
MV411, and U937 were obtained from American Type Culture Collection (ATCC, 
Rockville, MD, USA) and cultured in RPMI medium supplemented with 10% fetal 
bovine serum and 1% penicillin/streptomycin at 37°C with 5% CO2. The patient 
derived xenograft models (CCHMC-23, CCHMC-7, CCHMC-9, and CCHMC-35), 
were established at Cincinnati Children’s Hospital Medical Center from 
specimens acquired under an IRB-approved protocol following informed consent. 
These primary specimens were established and expanded in NSGS mice at 
CCHMC and BM aspirates obtained from leukemic mice were frozen at -80°C in 
RPMI with 10% FBS and 10% DMSO until xenograft. Primary AML blasts were 
isolated from de-identified diluted whole marrow aspirate acquired from JGBCC 
biorepository with informed consent and under IRB guidelines (IRB#13.0188), by 
Histopaque gradient and centrifugation at 500 x g for 20 minutes at room 
temperature. Human CD34+ hematopoietic stem cells purified from umbilical 
cord blood were obtained from AllCells, Alameda, California, USA).      
In vivo studies. NRG (NOD/RAG1/2−/−IL2Rγ−/−, stock no: 007799) and NRGS 
(NOD/RAG1/2−/−IL2Rγ−/−Tg[CMV-IL3,CSF2,KITLG]1Eav/J, stock no: 024099) 
mice producing 2-4 ng/ml of human IL-3, GM-CSF, and SCF108 were obtained 
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from Jackson laboratories, and bred and maintained under standard conditions in 
the University of Louisville Rodent Research Facility (RRF) on a 12-hour light/12-
hour dark cycle with food and water provided ad libitum. Animal procedures were 
approved by the Institutional Animal Care and Use Committee. For all cell line 
derived xenograft studies and the human HSC study mice received 5 x 10^5 
cells, and for all passaged patient derived xenograft studies 1.25 x 10^5 human 
cells suspended in 200µl PBS per mouse by bolus intravenous injection. 
Similarly, mice engrafted with the primary patient sample JGB-AML1 received 2 x 
10^6 cells in 200 µl per mouse by intravenous bolus. Mouse health was 
monitored for characteristic signs of leukemia like scruffiness, and hind-limb 
paralysis, at which time mice were euthanized. Analysis of human cell 
engraftment was conducted on a case-by-case basis when mice became 
moribund and humane endpoints were reached. 
5+3 Induction Chemotherapy Regimen. Using previously published data we 
established a similar 5+3 induction therapy regimen using intravenous bolus 
injection of doxorubicin (3 mg/kg, Days 1-3) combined with cytarabine (75 mg/kg, 
Days 1-5). Mice began treatment seven (or twenty five) days after transplantation 
of human leukemic cells with all mice receiving injections balanced to a final 
volume of 200ul PBS. Patients receiving standard 7+3 induction therapy (60 
mg/m2 doxorubicin and 100 mg/m2 cytarabine) get approximately 1.5 mg/kg 
doxorubicin and 2.5 mg/kg cytarabine. Therefore, similar to previously published 
work, our dose of doxorubicin was doubled and the cytarabine concentration 
increased by 20-fold in an attempt to achieve necessary plasma concentrations 
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of the drugs using a bolus injection as compared to continuous infusion given in 
clinical care.79   
Chemotherapeutics. Clinical formulations of both doxorubicin and cytarabine 
were obtained from the James Graham Brown Cancer Center as self-sealing 
vials containing 20 mg/10 ml or 2g/20ml respectively dissolved in saline, 
manufactured by APP a division of Fresenius Kabi USA LLC (Lake Zurich, IL). 
FACS Analysis. The spleen and BM cells were analyzed by FACS as previously 
described.109 Briefly cells were isolated from tissues, red blood cells were lysed 
and blocked for 10 mins at 4°C with Fc Block (#553142 BD Biosciences, Miami, 
FL, USA). The samples were then stained with the appropriate fluorophore 
conjugated anti-human antibody (Alexa 700-CD45, APC-CD11b, APC-CD19, PE-
CD3, PE-Cy.5-CD34, and PE-Cy.5-CD33) from BioLegend (San Diego, CA) for 
20 mins at 4° C and then analyzed on a Becton Dickinson FACScan with FlowJo. 
Statistical analysis. All statistics were performed using GraphPad Prism 6 
software. Unless specified below significance was determined by one-way 
ANOVA, followed by Tukey tests, using a cut off of P < 0.05. For all survival 
curves the log rank (Mantel-Cox) test was used, with a cut off of P < 0.05. 
RESULTS 
Cell line derived xenografts (CDXs) recapitulate clinical disease 
presentation in unconditioned NRG mice, but not unconditioned NRGS 
mice. 
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We first wanted to examine the differential engraftment efficiency of 
several commonly used, well- characterized human leukemic cell lines (MV411, 
K562, and U937) in unconditioned NRG and NRGS mice. All established cell 
lines showed high rates of successful engraftment in both strains, leading to 
leukemic disease progression and eventual euthanasia upon achievement of 
humane endpoints. (Fig. 2.1A) Interestingly, clinically disparate disease 
presentation was observed selectively in NRGS mice, which developed large 
intraperitoneal (IP) and lymphatic solid tumors with all cell lines tested. 
Conversely, NRG mice developed more clinically similar diffuse disease with the 
expected signs of leukemic disease progression like splenomegaly, upon 
xenograft of all established human cell lines. Necropsy of NRGS mice revealed 
disparity in preferential location of solid tumor formation with MV411 cells forming 
both IP and lymphatic tumors (Fig. 2.1B, bottom right), K562 cells had an 
extremely high potential to form tumors within the kidney (Fig. 2.1B, bottom 
left), and U937 cells formed only intra-splenic solid tumors (Fig. 2.1B, bottom 
middle). All mice showed high levels of engraftment with any of these cell lines, 
and showed pronounced leukemic infiltration of hematopoietic organs (Fig. 2.2A 
and 2.2B), but only NRG mice selectively failed to develop IP masses or 
hematopoietic solid tumors and showed a much more clinically relevant disease 
progression. Therefore, these studies provide compelling evidence that NRG 





Figure 2.1. Engraftment of established human AML cell lines in NRG and 
NRGS mice. (A) Survival curves of unconditioned NRG and NRGS mice post IV 
xenograft of 5 x 105 of each respective cell line, K562, U937, and MV411. (B) 
NRG mice transplanted with human AML cell lines showed normal leukemic 
progression with diffuse disease and splenomegaly (as depicted), whereas 
NRGS mice developed solid splenic tumors (U937), solid IP tumors (K562, 
MV411), and solid lymphatic tumors (MV411). (C) Box-and-whisker plots 
showing the percentage of detectable human cells in the spleens and BM of 
NRG (n = 5) and NRGS (n = 5) mice, as quantified by flow cytometry for human 
CD45. AML, acute myeloid leukemia; BM, bone marrow; IP, intraperitoneal. 
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Figure 2.2 H&E staining of spleen sections from NRG and NRGS mice 
xenografted with established human cell lines. (A) H&E-stained sections of 
representative formalin-fixed spleens from unconditioned NRG mice IV 
xenografted with 5 x 105 K562, MV411, or U937 cells per mouse suspended in 
200 mL of PBS. (B) Representative spleens from unconditioned NRGS mice IV 
xenografted with 5 x 105 K562, MV411, or U937 cells per mouse suspended in 
200 mL of PBS. PBS, phosphate-buffered saline. 
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Patient derived xenografts (PDXs) in unconditioned NRG and NRGS mice. 
We next examined the comparative engraftment efficiency of several 
patient-derived AML samples in both NRG and NRGS mice. Patient-derived 
samples were acquired as secondary transplants from NSGS mice harboring 
pediatric patient leukemia taken upon relapse, and three of the four samples 
displayed MLL translocations, whereas the final sample tested was 
cytogenetically normal (Fig. 2.3A). Leukemic disease progression eventually 
requiring euthanasia occurred in all NRGS mice irrespective of sample origin, 
while all NRG mice survived until the 100-day study endpoint without overt signs 
of disease (Fig. 2.3B). As expected efficient engraftment and leukemic infiltration 
of the hematopoietic compartment occurred with all four patient-derived samples 
in NRGS mice, whereas three of the four patient samples tested (CCHC-7, 
CCHC-23, and CCHC-35) showed virtually no useful engraftment (<5%) in NRG 
mice (Fig. 2.3C). Interestingly, large numbers of human cells were detected in 
the hematopoietic organs of NRG mice engrafted with CCHC-9 cells, but without 
symptomatic leukemic disease progression. Furthermore, no IP or lymphatic 
solid tumors formed in NRGS mice harboring PDXs, thus providing convincing 
evidence that NRGS mice, but not NRG mice, are uniquely suited for studies 
involving patient-derived leukemia cells. 
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Figure 2.3. Engraftment of patient-derived AML cells in NRG and NRGS 
mice. (A) All patient samples were initially obtained from pediatric patients upon 
relapse and passaged once through NSGS mice. All xenograft experiments 
performed in these studies utilized the BM of NSGS mice harboring high levels of 
each respective patient leukemic cells, as quantified by flow cytometry for human 
CD45. (B) Survival curves of NRG and NRGS mice after IV xenograft of 1.25 x 
105 human cells of each respective patient sample. Mice showing no signs of 
disease were euthanized 100 days after xenograft, the end-point of the study. (C) 
Box-and-whisker plots showing the percent of detectable human cells in the 
spleens and BM of NRG (n = 5) and NRGS (n = 5) mice, as quantified by flow 
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Humanization potential of unconditioned NRG and NRGS mice using 
purified human CD34+ HSCs. 
Given the recent push for the development of humanized mice bearing 
functional human immunity, we next examined the differential engraftment 
potential and the multilineage expansion of normal human CD34+ HSCs. CD34+ 
cells purified from umbilical cord blood (Fig. 2.4A) were transplanted into 
unconditioned NRG and NRGS mice, but only NRGS mice showed significant, 
durable engraftment of human hematopoietic cells 105 days later. Human cells 
were still detected in the hematopoietic organs of NRG mice, albeit at an 
extremely low percentage. Hematoxylin and eosin staining of spleen sections 
from NRGS mice revealed distinct patches of human cells absent in NRG mice, 
likely human HSCs undergoing extramedullary hematopoiesis (Fig. 2.4B) 
Multilineage expansion of human myeloid cells, pre-B cells, and T cells was 
observed selectively in NRGS mice, as characterized by surface expression of 
human CD19, CD33, and CD3 respectively (Fig. 2.4C). In contrast to previously 
published work indicating transgenic human cytokine expression is 
counterproductive to human HSC engraftment, we show that unconditioned 
NRGS mice retain high levels of human HSCs (huCD45+/huCD34+) in the spleen 
(Fig. 2.5A) and BM (Fig. 2.5B) even 105 days after xenotransplantation. 
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Figure 2.4. Comparative humanization potential of NRG and NRGS mice 
using human umbilical cord-derived CD34+ HSCs. (A) Histogram showing the 
percentage of human CD34+ cells purified from UCB before xenotransplantation. 
Blue indicates unstained cells and red indicates cells stained with antihuman 
CD34-PE/Cy5. (B) Immunohistochemistry analysis with H&E staining of 
representative NRG and NRGS spleens. Distinct patches of human cells are 
clearly visible only in NRGS spleens. (C) Box-and-whisker plots showing the 
percentage of human cells in the spleens and BM of NRG (n = 3) and NRGS (n = 
3) mice 105 days after transplantation of 5 x 105 human CD34+ cells and lineage
analysis by FACS staining using antihuman CD45-Alexa Fluor 700 (human pan-
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hematopoietic), CD19-APC (pan-B cell), and CD33-PE/Cy5 (pan-myeloid). UCB, 
umbilical cord blood. 
51 
Figure 2.5. Comparison of long-term engraftment of mature and stem 
human hematopoietic cells in unconditioned NRG and NRGS mice. (A) 
Representative flow plots and relative percentages of human stem 
(huCD45+/huCD34+) and mature (huCD45+/huCD34-) hematopoietic cells in the 
spleens of unconditioned NRG (n = 5) and NRGS (n = 5) mice 105 days after 
transplantation of 5 x 105 human CD34+ UBC cells, indicating significantly higher 
engraftment of both stem and mature human hematopoietic cells. (B) 
Representative flow plots and relative percentages of mature and stem human 
hematopoietic cells detected in the BM of unconditioned NRG and NRGS mice 
showing highly significant enrichment of both stem and mature human 
hematopoietic cells selectively in NRGS mice. 
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Establishment and comparison of clinically similar induction therapy 
dosing regimen in unconditioned NRG and NRGS mice. 
Truly useful AML xenograft models also require the ability to model SOC 
therapeutic outcomes, which in current clinical practice relies solely on the 
cytotoxic combination of an anthracycline and cytarabine. Therefore, we next 
examined the tolerability and efficacy of an adapted 5+3 induction regimen in 
both NRG and NRGS mice xenografted with human leukemic cells. Xenograft of 
the established cell lines MV411 and K562 resulted in solid tumor formation and 
clinically disparate disease presentation in NRGS mice. Mice injected with U937 
cells show similar survival trajectories, and engraftment efficiency in both strains, 
with NRGS solid tumor formation restricted to the spleen. Further, given the 
previous findings that PDX samples fail to engraft efficiently in NRG mice we 
chose U937 cells to examine comparative SOC therapeutic outcomes in both 
unconditioned NRG and NRGS mice. NRG and NRGS mice were able to tolerate 
our adapted 5+3 bolus IV induction therapy regimen, and all treated mice showed 
highly significant enhancement in survival as compared to vehicle-injected 
controls (Fig 2.6A). Our findings indicate that both strains are tolerant of a more 
clinically similar induction dosing regimen, and furthermore induction therapy in 
efficacious in treating disease (Fig 2.6B). Comparison of PDX induction 
sensitivity in NRG and NRGS mice proved a challenge as none of the four 
patient samples (CCHC-7, CCHC-9, CCHC-23, and CCHC-35) gave rise to 
leukemia in NRG mice at the time points examined. Although the inherent 
limitations of NRG prevented comparative examination of SOC therapeutic 
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outcomes with patient-derived AML xenografts, we still felt that it was important 
to test the efficacy of our regimen against AML PDXs. Therefore, unconditioned 
NRG and NRGS mice were engrafted with the patient sample CCHC-23 and 5+3 
induction therapy was initiated 7 days post xenograft. Again, 5+3 induction 
therapy significantly prolonged the life of all treated NRGS mice compared to 
vehicle-injected controls (Fig 2.6C), and therapy significantly reduced the 
leukemic burden. NRG mice in this study again failed to develop disease and 
survived until the experimental endpoint. Similarly, our adapted 5+3 induction 
therapy regimen was also efficacious in significantly prolonging the life of NRGS 
mice harboring either CCHC-7 or CCHC-9 PDXs (Fig 2.6D). Take together these 
findings indicate that our newly established adapted 5+3 induction therapy 
regimen is efficacious against several different patient-derived AMLs of varied 
etiology, at rates comparable to those observed in the aforementioned study 
using the established U937 cell line. These data are crucial to establishing the 
feasibility and efficacy of modeling SOC induction therapeutic outcomes in mice 








Figure 2.6 Comparison of standard of care chemotherapeutic response 
using 5+3 induction regimen in NRG and NRGS mice harboring cell line or 
patient-derived leukemia. (A) Survival curves for unconditioned NRG (n = 5) 
and NRGS (n = 5) mice engrafted with 5 x 105 U937 cells and subsequently 
treated with a 5+3 induction regimen [3 mg/kg doxorubicin (days 1-3) and 75 
mg/kg cytarabine (all 5 days)] or the vehicle (PBS) by IV injection 7 days after 
xenograft. (B) Box-and-whisker plots showing significant differences in the 
percentage of human cells detected in the spleens and BM of the NRG or NRGS 
mice from the study in (A). (C) Survival curves and box-and-whisker plots 
showing the percentage of human cells engraftment in unconditioned NRG (n = 5 
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per group) and NRGS (n = 5 per group) mice xenografted with 1.25 x 105 CCHC-
23 cells, and subsequently treated with 5+3 induction or the vehicle 7 days after 
xenograft. NRG mice failed to develop disease and survived until the endpoint of 
the study with or without induction therapy. (D) Survival curves showing 
significantly prolonged survival of unconditioned NRGS mice treated with 5+3 
induction using two additional patient xenografts, CCHC-7 and CCHC-9, to 
confirm therapeutic efficacy in multiple PDX samples. PBS, phosphate-buffered 
saline. 
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Dose escalation and modulation of adapted 5+3 induction regimen in AML 
PDX bearing NRGS mice. 
Having established the tolerability of NRG and NRGS mice to our adapted 
5+3 induction therapy regimen, we next wanted to test the limits of our model 
system by doubling the doses of both chemotherapeutics. Comparable to studies 
in human patients, the dose-limiting agent in this study was determined to be the 
anthracycline doxorubicin. Cohorts of mice receiving double the dose of 
doxorubicin showed widespread toxicity and mortality (7 of 10 mice). 
Interestingly, doubling of the cytarabine dose of cytarabine showed no overt 
increase in signs of toxicity as determined by weight loss, with no change in the 
survival trajectory compared to our standard 5+3 induction therapy (Fig. 2.7A, 
top). Perhaps, most intriguingly the few mice that survived treatment with double 
the dose of doxorubicin (6 mg/kg) showed no signs of leukemia at the endpoint of 
the study (Fig. 2.7A, bottom). When taken together these data are highly 
significant as they suggest that with proper optimization of drug concentration 
and dosing schedule it may be possible to achieve a “remission-like” phenotype 
in murine PDX models, a feature that closely recapitulates patient experience of 
AML. Up to 75% of de novo AML patients experience complete remission with 
only one cycle of induction therapy, with the majority of mortality being driven by 
refractory relapsed disease, again highlighting the importance of our findings in 
the accurate modeling of patient AML outcomes. Finally, in an effort to more 
faithfully recapitulate clinical therapy of AML we examined how modulation of 
treatment initiation timing affected therapeutic efficacy of our 5+3 induction 
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therapy 7 days and 25 days post leukemic xenograft. Concurrent with previously 
published reports we found that survival was significantly different between the 
cohorts receiving induction therapy 7 days or 25 days post xenograft, with mice 
receiving chemotherapy earlier surviving longer (Fig 2.7B). Finally, further 
investigation and optimization of treatment schedules may allow the development 
of an AML PDX model that can also accurately recapitulate clinical treatment 














Figure 2.7. Escalation of 5+3 induction chemotherapy and modulation of 
timing of chemotherapy initiation. (A) Survival curves of unconditioned NRGS 
mice (n = 5 per group) xenografted with 1.25 x 10^5 CCHC-23 cells and 
subsequently treated with 5+3 induction therapy this time with either double the 
dose of both drugs (6 mg/kg doxorubicin, 150 mg/kg cytarabine), double the dose 
of each drug singly without manipulation of concentration of the other or 1.5X the 
standard dose of doxorubicin (4.5 mg/kg, 75 mg/kg cytarabine). Box-and-whisker 
plots show the percentage of human cells detected in the spleen or BM in each 
treatment escalation group. (B) Survival curves of unconditioned NRGS mice (n = 
5 per group) xenografted with 1.25 x 105 CCHC-23 cells and treated with 5+3 
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induction 7 days after xenotransplantation or 25 days after xenotransplantation. 
Box-and-whisker plots show the percentage of human cells detected in the 
spleens and BM of NRGS mice upon disease progression and euthanasia after 





















Primary patient sample engraftment in unconditioned NRG and NRGS mice. 
The final line of investigation in this chapter examines the differential 
engraftment efficiency of an un-passaged primary patient AML sample (for 
detailed description, see Fig. 2.8A) obtained from a fresh BM aspirate from 
The James Graham Brown Cancer Center (Fig. 2.8B). 2 x 10^6 nucleated cells 
obtained from purification of the leukemic BM aspirate were injected into 
unconditioned NRG or NRGS mice, and all mice were euthanized 100 days post 
xenograft at which time the spleens and BM were analyzed for human CD45 
expression by flow cytometry. On average, NRGS mice had consistently higher 
rates of both spleen and BM engraftment as compared to NRG mice (Fig. 2.8C). 
Rates of splenic engraftment were consistently low in both NRG and NRGS mice 
(NRG average %huCD45= 3.07%, NRGS average %huCD45= 5.87%), with 
NRGS mice harboring approximately twice as many spleen resident human cells. 
H&E staining of spleen sections further confirmed these findings and revealed a 





Figure 2.8. Engraftment of primary patient-derived AML in NRG and NRGS 
mice. (A) Initial characterization of primary patient AML sample upon acquisition 
of BM aspirate and subsequent Ficoll gradient separation of mononucleated cells 
by flow cytometry for human CD45, CD34, CD33, CD19, CD14, and CD11b. (B) 
BM aspirate slide smear stained with Protocol Hema 3 showing both leukemic 
myeloblasts (red) and monoblasts (blue) (photograph acquired at 40X on Zeiss 
Observer AX10 microscope connected to a Sony Nex-5n HD camera) typical for 
M4 subtype AML. (C) Box-and-whisker plot showing the percentage of human 
cells detected in the spleens and BM of unconditioned NRG (n = 5) and NRGS (n 
= 5) mice 100 days after xenograft of 2 x 106 mononucleated cells. (D) 
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Immunohistochemistry of representative formalin-fixed, H&E-stained NRG and 
NRGS spleens xenografted with 2 x 106 mononuclear cells obtained from Ficoll 
gradient separation of clinical BM aspirate.
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CHAPTER 3 
PERTURBATION OF MET/SAM METABOLISM INDUCES APOPTOSIS, 
ALTERS HISTONE METHYLATION DYNAMICS, AND DECREASES DOT1L 
EXPRESSION IN MLL-TRANSLOCATED LEUKEMIA PROLONGING 
SURVIVAL IN ADVANCED PATIENT AML XENOGRAFT MODEL 
INTRODUCTION 
Mixed lineage leukemia 1 (MLL) gene rearrangement is a defining feature 
of a unique group of particularly aggressive and chemotherapy resistant acute 
leukemias. Rearrangement of the MLL gene on chromosome 11q23 results in 
fusion to over 60 different partner genes, the large majority of MLL fusions 
occurring with just six common partners. Furthermore, MLL-rearrangement (MLL-
R) is detectable in 10% of leukemia cases, which have the overall worst 
prognosis among cytogenetically abnormal leukemias.110 Leukemias arising from 
MLL-R result in the aberrant expression of oncogenic MLL fusion proteins (MLL-
FPs), and typically manifest as either acute myeloid or acute lymphoid leukemias 
(AML or ALL), accounting for 10% of adult AML cases, and 70-80% of infant 
leukemias.111  Modern highly aggressive multiagent cytotoxic chemotherapy and 
hematopoietic stem cell transplantation (HSCT), has extended the overall 
disease-free survival of pediatric leukemia patients to approximately 90%. 
Unfortunately, patients diagnosed with MLL-R leukemia have a particularly poor
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prognosis with an overall survival less than 50%, and this prognosis is not 
improved by allogenic HSCT.112 Great advances have been made in 
understanding the unique molecular mechanisms that mediate MLL-R driven 
leukemogenesis, and recently studies have suggested MLL-R leukemias are 
largely driven and maintained through epigenetic dysregulation. The HMT 
disruptor of telomeric silencing 1-like (DOT1L) has come to the forefront as a 
critical mediator of MLL-FP mediated leukemogenesis and has been shown to be 
required for the development the development, maintenance, and progression of 
MLL-R leukemias. Despite our improved understanding of the unique signaling 
mechanisms underlying MLL-FP mediated leukemogenesis, these leukemias are 
generally still treated with cytotoxic remission induction chemotherapeutic 
regimens resulting in high rates of initial remission, but the 5-year event-free 
survival rates remains under 50% due to refractory relapse. Thus, novel 
treatment paradigms must be investigated specifically for the therapy MLL-R 
leukemias, alone and in combination with SOC cytotoxic induction 
chemotherapeutics. 
DOT1L, the HMT which catalyzes the sequential methylation of H3K79 at 
the promoters of actively transcribed genes, has been strongly implicated as a 
requisite driver of MLL-FP mediated leukemic transformation and progression. 
Chromosomal translocations cause the in-frame fusion of MLL to a variety of 
fusion partners, most frequently members of the SEC complex namely, AF4, 
AF6, AF9, AF10, and ENL.113 These oncogenic fusions can interact directly and 
indirectly with Dot1L, promoting aberrant recruitment to leukemogenic gene 
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promoters like the HoxA cluster or Meis1.56 Dot1L causes local hypermethylation 
of H3K79 at these gene promoters inducing their aberrant expression causing 
leukemic transformation resulting in either AML or ALL.57 Several independent 
studies have shown through pharmacologic and genetic methods that Dot1L 
expression and function are required for both leukemic transformation and 
maintenance in vitro and in vivo. Consistent with this paradigm genetic deletion 
of DOT1L stops the leukemic transformation of normal HSCs transfected to 
express MLL fusions and new small molecule inhibitors of Dot1L are selectively 
toxic to MLL fusion driven leukemia cells in vitro and in xenograft 
models.62,65,67,114,115 The investigation of regulatory mechanisms controlled by 
Dot1L (cell cycle, development, transcription, DNA damage repair etc.) is 
exhaustive, however the regulation of Dot1L’s own expression remains unstudied 
and elusive. DOT1L mRNA is expressed ubiquitously in all organs at varying 
levels, and its level is dynamically regulated during the cell cycle as are the levels 
of H3K79me1,2,3.116,117 DOT1L-knockout cells transformed with MLL-fusion 
proteins, DOT1L siRNA transfected human lung cancer cells, and DOT1L-
knockout murine yolk sac-derived erythroid progenitors all undergo G1 cycle 
arrest and eventual cell death.118-120 Given the unique dependence of MLL-FPs 
on epigenetic dysregulation to drive leukemogenesis through aberrant activating 
histone methylation at leukemogenic promoters, we sought to investigate 
perturbation of Met/SAM metabolism as a novel therapeutic strategy for MLL-R 
leukemias. 
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The Met/SAM metabolic pathway is essential for cellular methylation 
reactions, including those involved in epigenetic gene regulation, as SAM serves 
as the primary methyl donor for most cellular methylation reactions, including 
DNA, RNA, lipids and histones (both arginine and lysine).34,35 In addition to being 
the principal methyl donor, SAM also serves as the sole source of the 
propylamine moiety required for polyamine biosynthesis.69,70 The biologically 
usable SAM moiety is synthesized from methionine by the enzyme MATIIA, and 
upon enzyme mediated donation of the SAM methyl group forms the product 
SAH, which is further metabolized by SAH hydrolase (SAHH) to form 
homocysteine.71 Homocysteine is an obligatory intermediate in the 
transsulfuration pathway, and serves as the precursor for glutathione synthesis, 
and alternatively homocysteine can be recycled back into methionine by the 
enzyme MTR, which catalyzes the final step in methionine regeneration by 
simultaneously converting 5-methyltetrahydrofolate in the biologically active 
cofactor tetrahydrofolate while transferring a methyl moiety to homocysteine 
starting the cycle again.72 Importantly, the intracellular ratio of SAM:SAH dictates 
the overall methylation potential of the cell, with SAH accumulation resulting in 
global feedback inhibition of cellular methylation reactions, including epigenetic 
methylation of DNA or histones.73 
Therefore, we hypothesized that Met/SAM metabolic flux and expression 
of the aforementioned enzymatic mediators are required at high levels selectively 
by MLL-R leukemia cells, to maintain and enforce aberrant histone methylation 
contributing to the leukemic phenotype. Unlike genetic abnormalities, epigenetic 
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modifications are frequently reversible, and therefore may provide new 
opportunities for targeted pharmacological therapies for MLL-R leukemias. 
Published literature targeting this pathway specifically in MLL-R leukemia is non-
existent, and a very sparse body of work exists for targeting this pathway as a 
general antileukemic therapy, with studies limited to small in vitro studies using 
established human cell lines, and single agent pharmacological inhibition of 
MATIIA or SAHH.121  Thus, we rigorously investigated methionine deprivation 
with and without inhibition of enzymatic mediators of the biosynthetic pathway in 
vitro and in combination with SOC cytotoxic induction therapy in vivo, as a novel 
epigenetic treatment paradigm for MLL-R leukemias. 
Here, we show for the first time to our knowledge that perturbation of 
Met/SAM metabolism is cytotoxic to MLL-FP expressing cells and induces 
apoptosis and DNA damage. Furthermore, perturbation of this critical metabolic 
pathway through methionine restriction or pharmacologic inhibition of SAH 
metabolism resulted in alteration of intracellular metabolite pools and overall 
methylation potential. Finally, we found that perturbation of Met/SAM metabolism 
and subsequently methylation potential, alters histone methylation dynamics 
globally and specifically at the DOT1L promoter, decreasing its expression and 
function in MLL-FP expressing cell lines and patient cells. In vivo pharmacologic 
perturbation of Met/SAM metabolism through SAHH inhibition, significantly 
prolonged the survival of mice harboring aggressive MLL-R patient leukemia in 
combination with a clinically similar regimen of cytotoxic induction therapy 
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combining doxorubicin and cytarabine. Thus, targeting Met/SAM metabolism may 
provide a novel therapeutic vulnerability against MLL fusion driven leukemia. 
MATERIAL AND METHODS 
Cell culture and Patient Samples. All established human leukemia cell lines 
MV411, RS411, and K562 were obtained from American Type Culture Collection 
(ATCC, Rockville, MD, USA) and cultured in standard RPMI medium 
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin at 
37°C with 5% CO2. Patient derived xenografts (CCHC-7, CCHC-9, and CCHC-
23) were established and expanded at Cincinnati Children’s Hospital Medical
Center in NSGS mice from primary pediatric specimens aquired under an IRB-
approved protocol following informed consent at time of relapse. Following 
engraftment and expansion in NSGS mice, resulting in terminal leukemic disease 
and euthanasia, we received the harvested BM aspirates from leukemic mice 
frozen at -80°C in RPMI with 10% FBS and 10% DMSO until xenograft. CCHC-7 
cells were also cultured in vitro in standard RPMI medium supplemented with 
10% fetal bovine serum, 1% penicillin/streptomycin, and human cytokines (SCF, 
FLT3L, TPO, IL-3, and IL-6) at 37°C with 5% CO2. 
Annexin V/Propidum Iodide Staining for Apoptotic Cells. Cell death was 
analyzed and quantified by FACS staining for Annexin V and propidium iodide 
(PI). Briefly, cells were thoroughly washed twice with ice cold PBS following 
exposure to experimental conditions and resuspended in 300ul of 1X Annexin 
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binding buffer. Next cells were incubated with 1µL of anti-Annexin V antibody 
conjugated to APC (catalog #640920, BioLegend San Diego, CA, USA) and 4µL 
of 1 mg/ml PI solution (Sigma-Aldrich St. Louis, MO, USA) for 15 min at 4°C, 
followed by analysis on a Becton Dickinson FACScan using FlowJo software. 
Protein Isolation/Quantification and Western Blot Analysis. Protein was 
isolated from cells in CHAPS lysis buffer, and quantified as previously 
described.122 Western blot analysis was then conducted as previously described 
using 30µg of protein for experiments involving total protein lysates and 15µg of 
protein for experiments involving purified histones, using 1:5000 or 1:2000 
dilutions respectively for primary antibodies and 1:20000 dilution of secondary 
antibodies. Proteins of interest were then detected by addition of 
chemiluminescence substrate. 
SAM/SAH Reverse Competition ELISA. Intracellular metabolites were isolated 
on ice by sonication of 10 x 10^6 cells per timepoint in 1ml of ice cold PBS using 
a 30 kHz sonnicator with probe at 30% amplitude for three 20 second cycles with 
one minute breaks between sonication. Cell debris was removed by high speed 
centrifugation and the resultant supernatant was snap frozen in liquid nitrogen 
and immediately stored at -80°C to prevent metabolite degradation. 
Quantification of intracellular SAM and SAH concentration was then conducted 
using the SAM/SAH ELISA Combo Kit from Cell Biolabs, INC. (catalog #STA-
671-C, San Diego, California, USA) following the manufacturers’ protocol. 
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Histone Isolation. Histones were isolated from cellular nuclei by acid extraction 
as follows. First cells were harvested and washed twice in ice cold PBS and then 
resuspended in Triton Extraction Buffer(TEB: PBS containing 0.5% Triton X 100, 
2 mM phenylmethylsulfonyl fluoride (PMSF), 0.02% NaN3) at a cell density of 107 
cells per ml per timepoint. Cells were lysed by ten minute incubation in TEB 
buffer at 4°C with gentle stirring followed by centrifugation at 6500 x g for ten 
minutes at 4°C to pellet the nuclei. The supernatant was discarded and the nuclei 
resuspended and washed in half the original volume of TEB buffer, followed by 
centrifugation as before. The supernatant was discarded and the nuclei pellet 
was resuspended in 100µL of 0.2 N HCl and placed at 4°C overnight to acid 
extract histones. The following day samples were centrifuged at 6500 x g for 10 
min to pellet debris and the supernatant was collected and HCl neutralized by 
addition of 10µL of 2M NaOH. Protein content was then determined using the 
BCA assay. 
Chromatin Immunopreciptation (ChIP). Chromatin fixation, isolation, digestion, 
and immunoprecipitation was performed as previously described in detail.123 
ChIP antibodies detecting anti-H3K4me3, anti-H3K27me3, and anti-H3K79me2 
were used for immunoprecipitation followed by ChIP quantitative RT-PCR as 
described earlier using DOT1L promoter specific primers. Further, similar 
quantitative RT-PCR was performed on immunoprecipitated chromatin using 
primers designed against a non-specific region approximately 6 kb upstream of 
the transcription start site (TSS) as a control to ensure that differential results are 
truly DOT1L promoter specific and not technique driven. DOT1L promoter 
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specific primers were designed just upstream of putative transcription factor 
consensus sites as determined by MotifMap software, and a detailed promoter 
map including primer binding sites can be found in Fig. 5A.         
 
RT-PCR. RT-PCR was performed on immunoprecipitated genomic DNA (as 
detailed above) or total isolated RNA reverse transcribed to cDNA as previously 
described.122 Primers for qPCR were designed against the promoter sequence or 
transcribed sequence using Primer Express 3.0 software (Applied Biosystems, 
Foster City, CA) per the manufacturer’s instructions for SYBR green dye assays. 
RT-PCR was performed using iTaq Universal Sybr Green Supermix (Bio-Rad) 
and relative expression levels were analyzed using ΔΔCT method data was 
normalized to 12.5% total chromatin inputs for RT-PCR following ChIP or β-actin 
expression for experiments on reverse transcribed mRNA. PCR reactions were 
analyzed on a BioRad CFX96, and a list of primer sequence and amplicon 
lengths can be found in Supplementary Table 1. 
 
Clinical Chemotherapeutics. Clinical formulations of both doxorubicin and 
cytarabine were obtained from the James Graham Brown Cancer Center as self-
sealing vials containing 20 mg/10 ml or 2g/20ml respectively dissolved in saline, 
manufactured by APP a division of Fresenius Kabi USA LLC (Lake Zurich, IL).    
 
In vivo xenograft studies. As previously described NRGS 
(NOD/RAG1/2−/−IL2Rγ−/−Tg[CMV-IL3,CSF2,KITLG]1Eav/J, stock no: 024099) 
mice producing 2-4 ng/ml of human IL-3, GM-CSF, and SCF108 were obtained 
from Jackson laboratories, and bred and maintained under standard conditions in 
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the University of Louisville Rodent Research Facility (RRF) on a 12-hour light/12-
hour dark cycle with food and water provided ad libitum. For all xenograft studies 
NRGS mice received 1.25 x 10^5 human cells (CCHC-7 or CCHC-9) suspended 
in 200µl PBS per mouse by bolus IV injection and n=5 for all study cohorts. Mice 
were then injected with an isovolumetric bolus of the vehicle (PBS), or treated 
with our previously described high intensity 5+3 induction regimen with or without 
25 mg/kg DZA dissolved in 200µl.124 
Statistical analysis. All statistics were performed using GraphPad Prism 8 
software. Unless specified below significance was determined by one-way 
ANOVA, followed by Tukey tests, using a cut off of P < 0.05. For all survival 
curves the log rank (Mantel-Cox) test was used, with a cut off of P < 0.05. 
RESULTS 
Perturbation of Met/SAM metabolism impairs cellular viability and induces 
apoptosis in MLL-FP expressing cell lines.  
We first sought to examine changes in cellular viability induced by 
alterations to Met/SAM metabolism on two MLL-AF4 expressing cell lines 
representing distinct leukemic lineages, MV411 and RS411 (AML and T-ALL 
respectively), as well as BCR-ABL driven K562 cells. We chose to target two 
distinct nodes of Met/SAM metabolism namely the synthesis of SAM by 
restriction of exogenous methionine, and downstream metabolism through 
pharmacological inhibition of SAH hydrolase  using the competitive inhibitor 3-
deazaadenosine (DZA), singly or in combination. Inhibition of downstream 
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Met/SAM metabolism by DZA induced a dose and time dependent impairment of 
cellular viability as quantified by Alamar Blue assay selectively in the MLL-AF4 
expressing cell lines, but not MLL-FP independent K562 cells (Fig. 3.1A). 
Similarly, decreasing concentrations of exogenous methionine also impair 
cellular viability (Fig. 3.1B). Using the data obtained from both dose curves we 
determined an appropriate concentration (15uM) of DZA, and timeframe to 
investigate methionine deprivation without overt toxic effects, for all further 
studies. Annexin V staining revealed that methionine deprivation and/or inhibition 
of SAH metabolism potently induced apoptosis MV411 cells, with the 
combination producing an additive increase in apoptosis. Interestingly, in the 
timeframe investigated RS411 cells only underwent apoptosis in the presence of 
DZA, but additive effects were still observed with simultaneous methionine 
deprivation and DZA treatment. (Fig. 3.1C, middle) Conversely, K562 cells 
lacking MLL-FP expression, were resistant to apoptosis induction through either 
methionine deprivation or inhibition of downstream SAHH mediated metabolism 
(Fig. 3.1C, right). Changes in protein expression corresponding the induction of 
apoptosis, like cleavage of PARP-1 and Caspase-3 were observed selectively in 
the MLL-AF4 expressing cell lines upon perturbation of Met/SAM metabolism, 
and consistent with the aforementioned Annexin V staining data RS411 cells only 
underwent apoptosis upon inhibition of downstream SAHH mediated metabolism, 
while MV411 cells underwent apoptosis upon deprivation of exogenous 
methionine or by SAHH inhibition (Fig. 3.1D).    
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Figure 3.1 Perturbation of Met/SAM metabolism potently induces apoptosis 
and reduces cell viability in established MLL-R leukemia cell lines . (A) 
Dose and time dependent reduction in relative survival of MLL-AF4 expressing 
MV411 (AML) and RS411 (ALL) cells treated with increasing concentrations DZA 
as quantified by Alamar Blue vitality assay 48 hours post treatment. K562 cells 
lacking MLL-fusion expression show no reduction in relative survival upon DZA 
treatment. (C) From left to right; Methionine deprivation or exposure to 15µM 
DZA potently induced apoptosis at 48 hours in MV411 cells singly, and the 
combination showed an additive increase in apoptosis as determined by Annexin 
V+ staining. RS411 cells only undergo apoptosis upon exposure to 15µM DZA 
and this effect is amplified by methionine deprivation. K562 cells lacking MLL-R 
show no induction of apoptosis 48 hour post DZA exposure or methionine 
deprivation. (D) Changes in protein expression corresponding with apoptosis 
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induction (PARP-1 and Caspase-3 cleavage) were observed under all 
experimental conditions in MV411 cells (left), while RS411 cells only undergo 
















Perturbation of Met/SAM metabolism influences intracellular metabolite 
pools, causing an increase in intracellular SAH and a decrease in 
methylation potential in MLL-AF4 expressing cells. 
After confirming that impairment of Met/SAM metabolism was selectively 
toxic to MLL-FP expressing cells, negatively impacted cellular viability, and 
induced apoptotic cell death we next sought to examine the impact on relevant 
intracellular metabolites, namely SAM and SAH, using a commercially available 
ELISA kit. These metabolites are of crucial importance as the ratio of intracellular 
SAM and SAH determines the overall cellular methylation potential, and the 
accumulation of SAH globally inhibits all methyltransferase reactions including 
those required for epigenetic regulation of gene expression (Fig. 3.2A). 8 hour 
exposure to 15uM DZA and/or methionine deprivation was sufficient to 
significantly increase intracellular SAH in MV411 cells, with a likely synergistic 
increase in SAH concentration upon simultaneous DZA treatment and 
methionine deprivation. By 24 hours MV411 cells showed a significant increase 
in intracellular SAH concentration under all conditions even methionine 
deprivation alone, however the increase is least pronounced with simultaneous 
methionine deprivation and DZA treatment, likely due to reduced metabolic flux. 
(Fig. 3.2B, left) Similarly, RS411 cells also showed a significant increase in 
intracellular SAH after 8hr or 24hr of exposure to DZA, but not simply by 
methionine deprivation, and no apparent synergy was observed with combined 
DZA treatment and methionine deprivation. (Fig. 3.2B, right) Interestingly, no 
significant change in intracellular SAM was observed in either cell line under any 
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of the experimental conditions including methionine deprivation suggesting these 
cells exhibit some capacity to recycle Met/SAM from other intracellular metabolite 
pools like homocysteine or 5-methylthioadenosine (Fig. 3.2C). Finally, we 
determined the overall cellular methylation potential, expressed as the ratio of 
intracellular SAM:SAH concentration normalized to untreated cells in methionine 
rich media, and found that 8 or 24hrs of methionine deprivation or exposure to 
DZA was sufficient to significantly lower overall cellular methylation potential in 
MV411 cells (Fig. 3.2D, left). RS411 cells show no significant changes in 
methylation potential upon short-term exposure to any experimental conditions, 
but show significant changes at 24hrs. As expected treatment with DZA 
significantly decreased cellular methylation potential with or without methionine, 
but methionine deprivation alone actually significantly increased cellular 
methylation potential in RS411 cells (Fig. 3.2D, right).       
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Figure 3.2 Disruption of Met/SAM metabolism increases intracellular SAH 
concentration and decreases overall methylation potential. (A) Simplified 
schematic of Met/SAM metabolism showing important enzymatic mediators, 
substrates and products. Deregulation of Met/SAM metabolism and subsequently 
methylation potential was achieved by targeting two distinct nodes, either by 
reducing synthesis of the methyl donor moiety SAM by methionine deprivation or 
pharmacological inhibition of downstream SAH metabolism and methionine 
recycling. (B) From left to right; Intracellular SAH concentration was increased in 
MV411 cells under all experimental conditions and timepoints, while only DZA 
mediated inhibition of SAH metabolism sufficiently increased intracellular SAH 
concentration in RS411 cells. (C) No significant changes were detected in the 
intracellular SAM concentration as compared to vehicle treated cells in 
methionine rich media, in either MV411 or RS411 cells under any experimental 
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conditions. (D) Overall cellular methylation potential (SAM:SAH) was significantly 
reduced in MV411 cells 24 hours post exposure to experimental conditions. 
RS411 cells only show significant reduction in methylation potential following 24 
hour exposure to DZA, and conversely a significant increase in methylation 
potential was observed following 24 hours of methionine deprivation. 
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Methionine deprivation or inhibition of downstream SAH metabolism alters 
global histone methylation dynamics in MLL-AF4 expressing leukemic cell 
lines. 
Next, we examined how perturbation of Met/SAM metabolism impacted 
global histone methylation dynamics in both MV411 and RS411 cells, by Western 
blot analysis on purified histone extracts. Initially, we chose to examine the most 
common activating histone modification H3K4Me3, which is heavily enriched at 
transcribed promoters, and the most common repressive modification 
H3K27me3. Methionine deprivation and/or SAHH inhibition through DZA 
treatment severely diminished global H3K4me3 levels in MV411 cells, while only 
treatment with DZA resulted in a global increase of the repressive modification 
H3K27me3 at all timepoints examined (Fig. 3.3A). RS411 cells show decreased 
levels of global H3K4me3 only in conditions of methionine deprivation, and when 
combined with DZA a more potent reduction is seen in the short term (Fig. 3.3B). 
Similar to MV411 cells, RS411 cells show a time dependent increase in global 
H3K27me3 only upon SAHH inhibition with or without methionine. MLL-R 
leukemias have been shown to be uniquely dependent on the misdirected 
enzymatic activity of the methyltransferase DOT1L to catalyze aberrant H3K79 
methylation and activation of leukemogenic gene expression. We next examined 
how perturbation of Met/SAM metabolism and methylation potential would impact 
global levels of H3K79me2, a modification required for the survival of MV411 and 
RS411 cells. Disruption of Met/SAM metabolism at either node dramatically 
reduced global H3K79me2 at all examined timepoints in MV411 cells, indicating 
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that they require sufficiently high levels of Met/SAM metabolic flux to maintain 
global levels of H3K79me2 (Fig. 3.3C). Global H3K79me2 was also reduced in 
RS411 cells at all timepoints examined (Fig. 3.3D) 
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Figure 3.3 Perturbation of Met/SAM metabolism alters global histone 
methylation dynamics and decreases DOT1L dependent global H3K79me2 
in MLL-R leukemia cell lines. (A) MV411 cells display a dramatic reduction in 
global levels of the activating H3K4me3 modification following methionine 
deprivation or DZA treatment, and a global increase in the repressive H3K27me3 
modification, only upon DZA mediated SAHH inhibition. (B) RS411 cells only 
display reduced levels of H3K4me3 only under conditions of methionine 
deprivation, but similar to MV411 cells show increased H3K27me3 after DZA 
mediated inhibition of SAH metabolism (right). (C) MV411 cells have profoundly 
reduced levels of MLL-R required H3K79me2 at all timepoints and experimental 
conditions examined. (D) RS411 cells also show a loss in global H3K79me2 with 
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differential reduction upon methionine deprivation and/or DZA treatment, but loss 
of this modification occurs more slowly as compared to MV411 cells.   
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Inhibition of SAH metabolism and/or methionine deprivation reduces 
mRNA expression and protein levels of the H3K79 methyltransferase 
DOT1L, and induces DNA damage. 
Perturbation of Met/SAM metabolism significantly decreased global levels 
of the required activating H3K79me2 modification in MV411 and RS411 cells. 
Therefore, we next examined how alterations to Met/SAM metabolism impacted 
the expression of the H3K79 methyltransferase DOT1L, at the mRNA and protein 
level. MV411 cells show significantly reduced DOT1L mRNA expression 
following 8hr treatment with DZA, with or without methionine deprivation, and by 
24hrs all three conditions significantly diminish DOT1L mRNA expression (Fig. 
3.4A, left). Consistent with the mRNA expression data, protein levels of DOT1L 
are also diminished in MV411 cells, and interestingly DNA damage was observed 
under conditions of DOT1L depletion (Fig. 3.4A, right). In alignment with 
previous cytotoxicity data a decrease in DOT1L mRNA was only observed upon 
DZA treatment of RS411 cells at 8 or 24hrs post exposure to experimental 
conditions, however by 36hrs DOT1L mRNA levels are decreased in RS411 cells 
upon methionine deprivation (Fig. 3.4B, left). Protein expression of DOT1L was 
reduced upon exposure to DZA at 8 and 24hrs post treatment, and under all 
experimental conditions by 48hrs, and again DNA damage was observed by 
pH2.AX foci formation (Fig. 3.4B, right). Conversely, DOT1L mRNA expression 
was significantly increased or remained unchanged in non-MLL rearranged K562 
cells, and very modest changes were observed in overall DOT1L protein levels 
(Fig. 3.4C). Finally, to further demonstrate correlation between Met/SAM 
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metabolic status, DOT1L expression, and apoptosis induction we either DZA 
treated RS411 cells for 24 hours followed by washout, or deprived RS411 cells of 
methionine for 48hrs followed by re-plating in methionine rich media, and tracked 
DOT1L and cleaved caspase-3 protein expression. As expected exposure to 
DZA for 24hrs or methionine deprivation for 48hrs decreased DOT1L expression 
and induced caspase-3 cleavage, followed by the subsequent increase in DOT1L 
expression and decrease in caspase-3 cleavage during recovery in drug free 
methionine rich media (Fig. 3.4D).   
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Figure 3.4 Alteration of Met/SAM metabolism reduces mRNA and protein 
expression of the required H3K79 methyltransferase DOT1L selectively in 
MLL-R leukemia cells. (A) DZA treatment or methionine deprivation of MV411 
cells significantly reduced DOT1L mRNA following 24 or 36 hour exposure to 
experimental conditions (left) and these changes are reflected in DOT1L protein 
levels (right). Reduction in DOT1L expression also correlated with the induction 
of DNA damage as determined by pH2.AX formation, likely due to the critical role 
DOT1L plays in regulation of the DNA damage repair response. (B) RS411 cells 
display a significant reduction in DOT1L mRNA (left) and protein levels (right) 
following DZA mediated SAHH inhibition, but not with methionine deprivation 
alone at the timepoints studied. Eventually, methionine deprivation alone 
significantly reduced DOT1L mRNA and protein expression in RS411 cells, and 
again DNA damage induction was detected only under conditions of DOT1L 
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reduction. (C) Non-MLL-R K562 cells lacking functional dependence on DOT1L 
show no significant changes in DOT1L mRNA expression (left) 24 hours post 
study initiation, however DOT1L mRNA was significantly reduced 36 hours after 
DZA exposure, but was significantly increased following 36 hours of methionine 
deprivation. Interestingly, modulation of DOT1L protein levels was observed even 
in K562 cells (right), and pH2.AX foci formation was also detected only under 
conditions of methionine deprivation in K562 cells. These results may suggest 
that appropriate regulation of Met/SAM metabolism and one-carbon sensing may 
directly play a more universal role in regulation of DOT1L expression and 
function in multiple cell types, regardless of MLL-R mediated functional 
dependence on DOT1L and H3K79 methylation.  
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Decreased expression of DOT1L is correlated to changes in histone 
methylation dynamics specifically at the DOT1L promoter. 
Chromatin immunoprecipitation (ChIP) was conducted on MV411 and 
RS411 cells under all experimental conditions, using antibodies against 
H3K4me3 (data not shown) and H3K27me3 followed by RT-PCR using DOT1L 
promoter specific primers. Promoter specific primer sets were designed against a 
DOT1L promoter region just upstream of two major putative transcription factor 
binding sites as predicted by MotifMap software. Control primers were also 
designed at a distal arbitrary location as an internal control to ensure that 
observed results were not due to technical bias (Fig. 3.5A). We found that 
inhibition of SAH metabolism and/or deprivation of exogenous methionine 
significantly elevated levels of the repressive H3K27me3 modification at the 
DOT1L promoter in MV411 cells 24hrs and 48hrs post exposure to experimental 
conditions, and there is likely a synergistic increase in H3K27me3 48hrs post 
combined methionine deprivation and DZA treatment (Fig. 3.5B). As we 
expected RS411 cells only showed increased levels of DOT1L promoter 
H3K27me3, upon DZA mediated inhibition of SAH metabolism, again matching 




Figure 3.5 Decreased expression of DOT1L is correlated to changes in 
histone methylation dynamics specifically at the DOT1L promoter. (A) 
DOT1L promoter map illustrating putative transcription factor binding sites as 
determined by MotifMap software, as well as the specific binding sites of the 
DOT1L promoter specific primers (P1) and the distal control primers. (B) MV411 
cells show significantly elevated levels of H3K27me3 occupancy at the DOT1L 
promoter following DZA treatment or methionine deprivation and by 48 hours an 
additive increase was observed under simultaneous methionine deprivation and 
DZA mediated SAHH inhibition. (C) RS411 cells exhibit significantly increased 
DOT1L promoter H3K27me3 occupancy following 24 hours of simultaneous 
methionine deprivation and DZA exposure, and by 48 hours DZA treatment but 
not methionine deprivation alone is sufficient to significantly elevate DOT1L 
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promoter H3K27me3 occupancy. (D) RS411 cells show a significant decrease in 
mRNA levels of HOXA9 and MEIS1, two well established DOT1L targets known 
to be required to maintain MLL-R mediated leukemogenesis, only upon DZA 
mediated inhibition of SAH metabolism but not methionine deprivation alone in 
agreement with our previous cytotoxicity and DOT1L expressional data in RS411 
cells. 
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Patient derived MLL-FP expressing leukemic blasts, similar to established 
cell lines, are sensitive to alterations in Met/SAM metabolism, and show 
corresponding changes in global and promoter specific histone 
methylation dynamics. 
We next examined if similar changes in histone methylation dynamics and 
DOT1L expression and function could be observed in patient derived MLL-FP 
expressing blasts (CCHC-7). CCHC-7 cells, bear an MLL-AF9 rearrangement 
and grow under standard culture conditions with human hematopoietic cytokines. 
We therefore plated these cells under all the previous experimental conditions 
and similarly examined apoptotic effects, alterations to global histone methylation 
dynamics, and changes in DOT1L expression. Like MV411 and RS411 cells, 
CCHC-7 cells undergo apoptosis, as determined by immunoblotting for caspase-
3 and PARP-1 cleavage (Fig. 3.6A). However, the cytotoxic effects of 
perturbation of Met/SAM metabolism in CCHC-7 cells more closely resemble 
RS411 cells, in that only DZA induced inhibition of SAHH with or without 
methionine resulted in apoptosis induction. Furthermore, we observed a 
decrease in overall DOT1L protein expression and similar changes in global 
histone methylation dynamics in the patient derived CCHC-7 cells, as compared 
to the tested MLL-FP cell lines (Fig. 3.6B). Interrogation of the DOT1L promoter 
by ChIP using a H3K27me3 specific antibody followed by RT-PCR using DOT1L 
promoter specific primers, showed a significant increase in H3K27me3 
occupancy at the DOT1L promoter in CCHC-7 cells (Fig. 3.6C). These results 
are highly similar to our in vitro studies utilizing the established MLL-AF4 
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expressing cell lines, we therefore felt confident in moving forward to in vivo 
studies. 
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Figure 3.6 Patient derived MLL-R leukemic blasts are sensitive to 
perturbation of Met/SAM metabolism, and show changes in global and 
DOT1L promoter specific histone methylation dynamics consistent with 
tested MLL-R cell lines. Combining DZA with 5+3 induction therapy 
significantly prolonged the life of mice harboring several different MLL-R 
patient derived xenografts. (A) Patient derived CCHC-7 cells behave similarly 
to the RS411 cell line and only undergo apoptosis following DZA mediated SAHH 
inhibiton with or without methionine deprivation as determined by PARP-1 and 
caspase-3 cleavage. Methionine deprivation for 48 hours was also sufficient to 
induce apoptosis and PARP-1 and caspase-3 cleavage. (B) CCHC-7 cells show 
a profound early loss in global H3K79me2 levels following 8 hours of exposure to 
experimental conditions, and this reduction was more modest 24 hours post 
exposure to either DZA or methionine deprivation alone. However, the 
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combination of simultaneous DZA mediated SAHH inhibition and methionine 
deprivation was still sufficient to decrease global H3K79me2 even after 24hrs 
(top). DOT1L protein expression was also reduced in CCHC-7 cells by 
methionine deprivation and/or DZA treatment (bottom). (C) CCHC-7 cell display 
significantly elevated levels of DOT1L promoter H3K27me3 occupancy 24 or 48 
hours after exposure to all experimental conditions and these changes likely 
correlate with the observed reduction in DOT1L protein expression and function 
(decreased H3K79me2). (D) NRGS mice (n=5 for all cohorts in all studies) were 
xenografted with 1.25 x 10^5 CCHC-7, CCHC-23, or CCHC-9 patient leukemic 
cells each bearing a unique MLL-R, and 7 days post xenotransplant mice began 
bolus intravenous infusion of isovolumetric amounts of 5+3 induction therapy (3 
mg/kg doxorubicin, Days 1-3 and 75 mg/kg cytarabine, Days 1-5), 5+3 induction 
plus 25 mg/kg DZA (Days 1-5), or the vehicle PBS alone. DZA in combination 
with 5+3 induction significantly prolonged the life of these mice as compared to 
either 5+3 induction therapy or vehicle treatment alone in all xenograft studies 
regardless of particular patient MLL-R, and excitingly two of the five mice bearing 
CCHC-9 xenografts completely failed to develop leukemic disease and survived 
till the endpoint of our study (far right).  
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Pharmacologic inhibition of SAH metabolism by DZA significantly prolongs 
the survival of mice xenografted with patient MLL-FP expressing leukemia, 
in combination with SOC induction therapy. 
Patient derived CCHC-7 cells were found to be highly sensitive to 
pharmacologic disruption of downstream SAH metabolism in vitro, and also 
displayed similar changes in DOT1L expression, and both DOT1L promoter 
specific and global histone methylation dynamics as compared to established 
MLL-AF4 expressing cell lines. Thus, we finally examined the in vivo efficacy of 
DZA mediated SAHH inhibition in a highly advanced and clinically relevant 
xenograft model of patient MLL-R leukemia. Cohorts of transgenic NRGS mice 
(n=5 per group) were xenografted with three induction refractory pediatric patient 
AML samples, each bearing a different MLL rearrangement. Seven days post 
xenograft the mice were given isovolumetric bolus intravenous injections of either 
saline, induction chemotherapeutics, or induction chemotherapeutics combined 
with 25 mg/kg DZA in a clinically similar and previously defined 5+3 regimen.124 
Combined treatment using 5+3 induction and DZA significantly prolonged the 
survival of NRGS mice xenografted with aggressive patient derived MLL-FP 
expressing leukemia, albeit to varying degrees. A modest but significant survival 
extension was seen in mice engrafted with either CCHC-7 or CCHC-23 cells, as 
compared to 5+3 induction therapy alone (Fig. 3.6D left, center). Excitingly, 
combinatorial therapy of mice harboring CCHC-9 leukemia significantly 
prolonged their survival, and two of five mice in the (5+3) + DZA cohort survived 
to the endpoint of the study without developing disease (Fig. 3.6D right).
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CHAPTER 4 
OVERALL DISCUSSION AND SUMMARY 
AML, and more broadly leukemia in general, is in actuality a heterogenous 
group of related hematopoietic dysplasias characterized by a block in 
hematopoietic differentiation, resulting in aberrant growth and proliferation. 
Disease presentation of human leukemia is uniquely heterogenous among 
cancers, and displays highly patient specific disparities in terms of morphology, 
cytogenetics, and epigenetics. However, approved frontline clinical induction 
therapy revolving around the cytotoxic combination of an anthracycline and 
cytarabine remains the only FDA approved therapy for AML, and treats AML in a 
“one size fits all” manner, regardless of patient specific disease etiology. Current 
preclinical investigation of novel AML therapeutics very rarely involves 
comparison to SOC chemotherapy. Furthermore, it has been well documented 
that preclinical in vivo animal models of patient disease consistently better predict 
the successful outcomes of novel experimental therapeutics in clinical trials. 
Therefore, the overall goal of this dissertation was two-fold, first to develop a 
more clinically relevant model of CDX or PDX AML that is capable of efficient 
engraftment of patient AML, humanization, can model the influence of human 
myeloid cytokine signaling, and most importantly tolerate an efficacious more
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clinically similar regimen of induction chemotherapy compared to the much more 
prevalent SCID-dependent AML xenograft models. 
Secondly, we sought to use our newly established advanced PDX model 
of MLL-translocated pediatric leukemia to confirm preliminary in vitro findings that 
perturbations of Met/SAM metabolism are cytotoxic to MLL-rearranged leukemia 
cells and alter global and promoter specific histone methylation dynamics 
decreasing the function and expression of the required H3K79 methyltransferase 
DOT1L. 
To address the first overall goal of developing a more advanced and 
clinically relevant murine xenograft model, we compared the usefulness of the 
relatively new and under-utilized SCID-independent immunodeficient NRG mice, 
and the related human myeloid cytokine expressing NRGS strain without 
preconditioning, in modeling of both malignant and normal human 
hematopoiesis. Initially, we examined comparative engraftment efficiency of 
human leukemic CDXs and PDXs in both NRG and NRGS mice. As expected, 
we found that human primary and secondary PDX samples engraft with high 
efficiency selectively in NRGS mice, but not NRG mice, likely due to their 
transgenic expression of human myeloid cytokines whose signaling is required 
for efficient engraftment. Remarkably, human CDXs showed irregular 
engraftment and clinically disparate disease progression in NRGS mice resulting 
in the formation of large IP and intra-lymphatic solid tumors, but showed 
canonical diffuse hematopoietic restricted disease presentation and progression 
in NRG mice. These effects are likely due to the constitutive whole body 
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expression of human myeloid cytokines driving the rapid growth and proliferation 
of established human leukemic CDXs in non-hematopoietic organs. Thus, our 
findings highlight the importance of selecting the correct strain of mice as 
contextually determined by the experimental design. 
Importantly, we also examined therapeutic outcomes and tolerability of 
SOC chemotherapeutic induction therapy, in a clinically similar 5+3 treatment 
regimen, and showed therapeutic efficacy against human CDXs and PDXs. 
Furthermore, these mice were tolerant of significantly higher doses of induction 
chemotherapeutics, as compared to more commonly used SCID mice, and these 
doses more closely recapitulate clinical patient therapy. Xenograft mouse models 
have consistently been shown to better predict the success of experimental 
chemotherapeutics in clinical trials, however most preclinical studies fail to also 
model SOC therapy (usually only vehicle or less frequently single agent therapy 
are used as study controls), both as a more relevant experimental control and 
additionally in the study of combinatorial therapies. Our findings validate the 
feasibility of modeling highly aggressive and clinically similar 5+3 induction 
therapy in RAG1 deficient (SCID independent) NRG and NRGS mice, and similar 
model systems may enhance investigation of highly efficacious novel single-
agent or combinatorial chemotherapeutics. 
In addition to modeling malignant human hematopoiesis, we also felt it 
was important to examine the utility of these two under used mouse strains in 
modeling normal hematopoiesis. Astonishingly, we found that even without 
expensive and/or time-consuming ablative preconditioning NRGS mice were able 
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to support the efficient durable engraftment and multilineage expansion of human 
CD34+ UBC derived HSCs. These results are highly significant as they contradict 
previous studies which demonstrate transgenic human hematopoietic cytokine 
production is counterproductive and diminishes human HSC engraftment and 
expansion. However, in contrast with the aforementioned studies for the sake of 
ease, cost, and high-throughput efficiency we chose to forgo the intense ablative 
preconditioning (pharmacological agents or irradiation) utilized in these studies, 
opting instead to used unconditioned animals. Ablative conditioning may render 
the murine BM microenvironment inhospitable to human HSC seeding or 
promote hematopoietic differentiation and loss of self-renewal in human HSCs. 
Thus, our findings indicate that not only is myeloablative conditioning 
unnecessary in NRGS mice, and may in fact be detrimental to long-term durable 
engraftment of human HSCs. 
To address the second overall goal of this dissertation, we next sought to 
utilize the aforementioned, and now well-characterized NRGS model system to 
further investigate our in vitro findings that perturbations of Met/SAM metabolism 
are cytotoxic, and deregulates the misdirected and required DOT1L / H3K79me 
signaling axis required to maintain survival and leukemic potential in MLL-R 
leukemia cells. We were able to show that perturbation of Met/SAM metabolism 
by targeting two distinct nodes, namely through deprivation of exogenous 
methionine or DZA mediated pharmacologic inhibition of downstream SAH 
metabolism, induced apoptosis in established MLL-R cell lines and patient 
derived MLL-R blasts, but not in MLL-R independent BCR-ABL expressing K562 
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cells. Furthermore, we determined that perturbation of this critical metabolic 
pathway also resulted in changes in global and promoter specific histone 
methylation dynamics including the global loss of the activating H3K4me3 and 
H3K79me2, and an increase in the repressive H3K27me3 globally and 
specifically at the DOT1L promoter, only in MLL-R leukemic cells. Interestingly, 
we also observed that perturbation of Met/SAM metabolism even reduced both 
mRNA and protein expression of the DOT1L methyltransferase, thus suggesting 
that some degree of feed-back one-carbon metabolic regulation exists controlling 
DOT1L expression and function in MLL-R leukemia cells. (Fig. 4.1) 
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Figure 4.1 One proposed mechanism by which perturbation of Met/SAM 
metabolism induces apoptosis in DOT1L dependent MLL-R leukemia cells. 
Our findings suggest that perturbation of Met/SAM metabolism reduces 
methylation potential and negatively impacts both expression and function of the 
requisite H3K79 methyltransferase DOT1L in MLL-R cell lines and patient blasts. 
Furthermore, under conditions of diminished methylation potential we observed a 
significant decrease in global H3K79me2 and an increase in the repressive 
H3K27me3 modification specifically at the DOT1L promoter, as well as a 
reduction in DOT1L mRNA and protein. Given the unique dependence of MLL-R 
leukemia on sufficiently high levels of DOT1L expression and function, our 
findings suggest that perturbation of Met/SAM metabolism may be a novel 
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therapeutic vulnerability specifically targeting the high levels of aberrant 
activating histone methylation required to maintain MLL-R mediated 
leukemogenic gene expression and phenotype.    
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We next confirmed that similar changes in histone methylation dynamics 
and cytotoxic effects occur in patient derived MLL-R leukemic blasts in vitro and 
therefore felt confident in testing this novel therapeutic paradigm against MLL-R 
PDXs, in our highly advanced in vivo human leukemia xenograft model. 
Excitingly, the addition of 25 mg/kg DZA to our standard 5+3 induction therapy 
regimen significantly prolonged the survival of NRGS mice bearing several 
unique MLL-R patient samples as compared to vehicle or 5+3 induction alone 
treated mice, and additionally no overt toxic effects were observed by weight 
loss. These results are even more promising as all patient PDX cells were 
acquired at the time of induction refractory relapse suggesting that perturbation 
of Met/SAM metabolism may be a valuable therapeutic adjuvant, especially 
during subsequent rounds of induction and/or consolidation therapy. Our studies 
provides in vivo proof of concept that targeting Met/SAM metabolism may be a 
unique vulnerability specifically against aggressive and poorly treated MLL-R 
leukemia, by deregulating the expressional axis controlled by the MLL-R 
epigenetic lesion. Finally, our findings also demonstrate the utility of our newly 
established highly advanced PDX leukemia model, especially in the investigation 
of novel combinatorial therapeutic treatment paradigms. 
In total, work outline in this dissertation highlights the need for 
implementation of more clinically relevant animal models of human leukemia, that 
model not only physiologically relevant disease progression, but also response to 
SOC cytotoxic induction therapy. Using our newly established mouse model of 
human leukemia in NRG and NRGS mice, we were able to test the in vivo utility 
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of targeting Met/SAM metabolism as a new treatment strategy specifically 
against MLL-R leukemias, and were able to show significant life extension in all 
mice treated in combination with DZA and 5+3 induction as compared to 5+3 
induction alone. In conclusion, our findings demonstrate the utility of our newly 
established murine PDX model, and furthermore provide support for the 
continued investigation of perturbation of Met/SAM metabolism as a potential 
new therapeutic approach against MLL-R leukemia in combination with SOC 
cytotoxic chemotherapy. 
STRENGTHS AND LIMITATIONS 
STRENGTHS 
The work presented in this dissertation, to our knowledge, is the first 
comprehensive study of the utility of the under-utilized SCID-independent NRG 
and NRGS mice in modeling malignant and normal human hematopoiesis. 
Previous preclinical studies on experimental leukemia therapeutics have 
depended heavily of chemotherapeutic intolerant SCID mouse models and 
therefore fail to account for SOC treatment outcomes, as either a more relevant 
control or in the investigation of adjuvant therapeutics. Our data conclusively 
shows for the first time that both NRG and NRGS mice can tolerated relevant 
doses of induction therapeutics in a clinically similar treatment regimen, and 
therapy is efficacious in delaying disease progression and prolongs life of mice 
harboring human CDXs or PDXs. Thus, our data challenges the hematological 
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field to abandon the widely favored SCID dependent murine model systems, in 
favor of RAG deficient strains tolerant of induction therapy, therefore not only 
model the unique heterogeneity of patient leukemic disease, but more 
importantly therapeutic response to SOC induction therapy. Truly efficacious 
experimental anti-leukemia therapeutics must be judged in comparison to SOC 
therapeutic outcomes, and additionally our new model system allows for 
investigation of novel combinatorial therapies. 
We next were the first to identify perturbation of Met/SAM metabolism as a 
novel vulnerability in vitro and in vivo against the now well-defined MLL-R 
epigenetic lesion, which maintains leukemogenic potential through aberrant 
activating histone methylation and subsequent anomalous expression of 
embryonic genes like the HOXA cluster or MEIS1. Our novel approach was to 
investigate perturbation of Met/SAM metabolism, which controls both methylation 
potential and methylation substrate availability, as a new therapeutic vulnerability 
given MLL-R leukemia’s necessity to maintain high levels of aberrant histone 
methylation to activate leukemogenic gene expression patterns crucial for 
survival and disease progression. Perturbation of this metabolic pathway was 
indeed toxic to MLL-R cells, induced apoptosis, and deregulated global and 
DOT1L promoter specific histone methylation dynamics, providing support for our 
initial hypothesis. We further demonstrated this point in vivo by showing 
significant survival extension of mice when treated in combination with SOC 
induction and the competitive SAHH inhibitor DZA as compared to induction 
alone, in our newly described NRGS PDX model system. 
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LIMITATIONS 
While we believe our newly characterized, highly advanced, and more 
clinically relevant human leukemia xenograft model is significantly superior to 
more commonly used SCID dependent preclinical models, there are still 
limitations to our NRG/NRGS model system. First and foremost, we demonstrate 
that the utility of each of these relatively new mouse strains is contextually limited 
by individual experimental design, more specifically NRG mice are well suited 
only for CDX studies while NRGS mice develop clinically disparate CDX disease 
progression, and should be used exclusively for highly efficient engraftment and 
progression of PDXs. Secondly, while our collaborators at Cincinnati Children’s 
Hospital have directly examined plasma levels of induction therapeutics in mice 
and calibrated their doses based on mouse pharmacokinetics and clinical patient 
plasma concentrations from literature, we have never directly examined plasma 
drug concentrations in our mice, instead basing our doses on their published 
studies. Regardless, our findings demonstrate the tolerability of these mice to 
aggressive chemotherapy, to be double that of more commonly used SCID 
dependent strains, and furthermore treatment is efficacious in prolonging survival 
and human CDX and PDX disease latency. 
Our work is the first to identify targeting of Met/SAM metabolism as a 
potential therapeutic vulnerability against MLL-R leukemias, by deregulating the 
required high levels of aberrant, activating DOT1L mediated H3K79 histone 
methylation to maintain survival and leukemogenic potential. However, our 
studies fail to elaborate on the essential nature of Met/SAM metabolism in a 
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myriad of other critical cellular processes like purine/pyrimidine biosynthesis, 
glutathione synthesis, 5-THF regeneration, etc. Perhaps our effects are mediated 
more profoundly through decreased metabolic flux through these pathways 
resulting in cytotoxicity and apoptosis induction. Furthermore, it is possible that 
methionine deprivation induces other starvation related effects, like a global 
decrease in all protein synthesis, and this may explain our observed decrease in 
DOT1L expression. However, MLL-R independent K562 cells show no significant 
change in global H3K79me2 levels and/or DOT1L mRNA and protein expression, 
again suggesting that these effects only occur in the context of MLL-R leukemia. 
Furthermore, differential effects were observed in sensitivity to targeting different 
nodes of Met/SAM metabolism and may suggest that inhibition of this pathway is 
only highly cytotoxic in MLL-R leukemias of myeloid origin or with other favorable 
cell type intrinsic characteristics. 
Finally, we were able to use our newly established NRGS PDX model 
system to demonstrate significant life extension in mice treated with a 
combination of SOC induction therapy and the SAHH inhibitor DZA, but never 
investigated single-agent DZA therapeutic outcomes, and our studies were 
limited by exclusively focusing on survival. Thus, we have no data from patient 
leukemic cells isolated from PDX bearing NRGS mice, showing concurrent 
changes in histone methylation dynamics as compared to our in vitro studies. 
Furthermore, perturbation of Met/SAM metabolism may likely show additive 
and/or synergistic effects with DNA-damaging induction chemotherapeutics, a 
possibility that remained uninvestigated in our studies.  These limitations were 
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taken into consideration, however considering this was the first preliminary 
investigation into targeting of Met/SAM metabolism in MLL-R leukemia, we 
simply wanted to investigate potential differential adjuvant therapeutic outcomes 
to determine whether this treatment paradigm was meritorious of future 
investigation. Furthermore, no clinically useable inhibitors of any Met/SAM 
metabolic enzymes exist, and most preclinical investigation, including this 
dissertation, relies on relatively non-specific substrate competitive inhibitors 
(cycloleucine, DZA, DZNep, adenosine dialdehyde, etc.). This changed in 2017, 
when a group from Pfizer discovered and characterized PF-9366 the first novel 
allosteric inhibitor of MATIIA, the enzyme responsible for the synthesis of SAM 
from methionine, capable of inhibition at physiologically reachable 
concentrations. Our findings now support the continued investigation of potent 
targeted inhibitors of Met/SAM metabolism, as a unique vulnerability specific to 
MLL-R leukemias. 
FUTURE DIRECTIONS 
While we have worked to extensively characterize and validate the utility 
of NRG and NRGS mice in modeling both normal and malignant human 
hematopoiesis, and further utilized our newly established model system to 
confirm our in vitro findings that perturbation of Met/SAM metabolism may be a 
unique therapeutic vulnerability in MLL-R leukemia. However, several important 
underlying mechanisms and questions remain unanswered in our studies, and 
thus the future directions are outlined below: 
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1. Optimization of both induction therapeutic dosing and timing in NRG and
NRGS mice.
We have shown that NRG and NRGS mice are tolerant of aggressive 5+3 
induction with 3 mg/kg doxorubicin and 75 mg/kg cytarabine, but 
widespread toxicity and decreased survival was observed when the 
concentration of doxorubicin was doubled to 6 mg/kg, irrespective of 
cytarabine dosage. Interestingly, the few mice that did survive our dose 
escalation study actually survived until the 100 day study endpoint with no 
symptomatic leukemic disease progression. These findings are highly 
exciting as they suggest that with careful optimization of the dose limiting 
anthracycline, we may be able to model the most predominant clinical 
outcome of leukemia, initial remission. Further, aging of the PDX 
harboring mice that receive remission inducing induction therapy, may 
actually allow for the development of refractory patient disease, even 
further increasing the preclinical modeling utility of the NRG/NRGS model 
system. In the future we also plan to examine how modulation of induction 
timing affects therapeutic outcomes, and to model other approved 
induction regimens like 7+3 therapy. 
2. Investigate the in vivo therapeutic potential of dietary methionine
restriction in mice harboring human leukemia xenografts.
Data outlined in Chapter 3 indicate that perturbation of Met/SAM 
metabolism by pharmacologic inhibition of SAHH using 25 mg/kg DZA 
significantly prolonged the survival of NRGS mice harboring aggressive 
patient MLL-R leukemia, in combination with 5+3 induction. However, the 
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therapeutic potential of dietary methionine restriction and 5+3 induction 
remains unstudied. In order to examine these potentially beneficial effects, 
we have established and treated two cohorts of NRGS mice harboring the 
same MLL-R PDX, and each cohort is fed either isocaloric chow 
containing 0.86% or 0.11% methionine respectively. Previously published 
studies have shown that modulation of dietary methionine is sufficient to 
alter histone methylation dynamics in mice and humans.125,126 Additionally, 
we may also observe toxicity ameliorative or chemotherapy enhancing 
effects, as several other studies have shown beneficial effects of 
methionine restriction on chemotherapeutic drug efficacy and tumor 
regression.127-129
3. Examine therapeutic efficacy of combined DZA treatment and methionine
restriction with 5+3 induction against patient MLL-R xenografts.
Our final line of future investigation aims to combine the observed 
beneficial effects of DZA treatment along with 5+3 induction, with the 
potential benefits of dietary methionine restriction. These studies may 
demonstrate even further enhanced improvement in treatment outcomes 
and amelioration of chemotherapeutic toxicity, especially if beneficial 
effects are seen in the studies described above combining dietary 
methionine restriction and 5+3 induction therapy. Further investigation 
may reveal targeting of Met/SAM metabolism as a bona fide therapeutic 
vulnerability inhibiting the aberrant activating histone methylation driven by 
the MLL-R epigenetic lesion.
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AML Acute myeloid leukemia 
BM Bone marrow 
SOC Standard of care 
FAB French-American-British 
APL Acute promyelocytic leukemia 
WHO World Health Organization 
CR Complete Remission 
IV Intravenous 
Ara-c Cytarabine 
MRD Minimal residual disease 
CN-AML Cytogenetically normal AML 
NPM1 Nucleophosmin 1 
FLT3 Fms-like tyrosine kinase 
DNMT3A DNA methyltransferase 3A 
FLT3-ITD FLT3 Internal Tandem Duplication 
OS Overall survival 
DFS Disease free survival 
HSC Hematopoietic stem cell 
HMT Histone Methyltransferase 
HDAC Histone Deacetylase 
MLL Mixed-lineage leukemia 
ALL Acute lymphocytic leukemia
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SEC Super elongation complex 
DOT1L Disruptor of telomeric silencing 1-like 
MLL-FP MLL fusion protein 
SAM S-adenosylmethionine 
Met Methionine 
MATIIA Methionine adenosyltransferase IIA 
SAH S-adenosylhomocysteine 
SAHH S-adenosylhomocysteine hydrolase 
MTR Methionine synthase 
LSC Leukemic stem cell 
SCID Severe combined immunodeficiency 
Prkdc DNA-activated catalytic polypeptide 
NOD Non-obese diabetic 
RAG Recombination activated gene 
NK Natural killer 
SF Steel factor 
SCF Stem cell factor 
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RRF Rodent research facility 
IP Intraperitoneal 
HSCT Hematopoietic stem cell transplant 
ChIP Chromatin immunoprecipitation 
PI Propidium iodide 
TSS Transcription start site
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